UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                      

Commission File No. 001-35083

 

Novanta Inc.

(Exact name of registrant as specified in its charter)

 

 

New Brunswick, Canada

 

98-0110412

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

 

 

125 Middlesex Turnpike

Bedford, Massachusetts, USA

 

01730

(Address of principal executive offices)

 

(Zip Code)

(781) 266-5700

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes       No  

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes       No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

  (Do not check if a smaller reporting company)

  

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes       No  

As of April 28, 2017, there were 34,549,524 of the Registrant’s common shares, no par value, issued and outstanding.

 

 


 

 

 

NOVANTA INC.

TABLE OF CONTENTS

 

Item No.

 

  

Page
No.

 

 

PART I — FINANCIAL INFORMATION

  

1

 

 

 

ITEM 1.

  

FINANCIAL STATEMENTS

  

1

 

 

 

 

  

CONSOLIDATED BALANCE SHEETS (unaudited)

  

1

 

 

 

 

  

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

  

2

 

 

 

 

  

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited)

  

3

 

 

 

 

  

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

  

4

 

 

 

 

  

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

  

5

 

 

 

ITEM 2.

  

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

  

23

 

 

 

ITEM 3.

  

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

  

33

 

 

 

ITEM 4.

  

CONTROLS AND PROCEDURES

  

33

 

 

PART II — OTHER INFORMATION

  

34

 

 

 

ITEM 1.

  

LEGAL PROCEEDINGS

  

34

 

 

 

ITEM 1A.

  

RISK FACTORS

  

34

 

 

 

ITEM 2.

  

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

  

34

 

 

 

ITEM 3.

  

DEFAULTS UPON SENIOR SECURITIES

  

34

 

 

 

ITEM 4.

  

MINE SAFETY DISCLOSURES

  

34

 

 

 

ITEM 5.

  

OTHER INFORMATION

  

34

 

 

 

ITEM 6.

  

EXHIBITS

  

35

 

 

SIGNATURES

  

37

 

 

EXHIBIT INDEX

  

38

 

 

 

 


 

 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

NOVANTA INC.

CONSOLIDATED BALANCE SHEETS

(In thousands of U.S. dollars or shares)

(Unaudited)

 

 

March 31,

 

 

December 31,

 

 

2017

 

 

2016

 

ASSETS

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

Cash and cash equivalents

$

80,014

 

 

$

68,108

 

Accounts receivable, net of allowance of $884 and $565, respectively

 

70,073

 

 

 

63,769

 

Inventories

 

71,019

 

 

 

59,745

 

Prepaid income taxes and income taxes receivable

 

2,740

 

 

 

2,058

 

Prepaid expenses and other current assets

 

6,139

 

 

 

5,570

 

Total current assets

 

229,985

 

 

 

199,250

 

Property, plant and equipment, net

 

36,792

 

 

 

35,421

 

Deferred tax assets

 

10,013

 

 

 

8,593

 

Other assets

 

3,835

 

 

 

12,502

 

Intangible assets, net

 

104,363

 

 

 

61,743

 

Goodwill

 

150,278

 

 

 

108,128

 

Total assets

$

535,266

 

 

$

425,637

 

LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

Current portion of long-term debt

$

7,368

 

 

$

7,366

 

Accounts payable

 

34,226

 

 

 

32,213

 

Income taxes payable

 

5,410

 

 

 

3,969

 

Accrued expenses and other current liabilities

 

30,941

 

 

 

26,948

 

Total current liabilities

 

77,945

 

 

 

70,496

 

Long-term debt

 

110,865

 

 

 

70,554

 

Deferred tax liabilities

 

8,254

 

 

 

1,294

 

Income taxes payable

 

6,043

 

 

 

5,710

 

Other liabilities

 

15,868

 

 

 

18,713

 

Total liabilities

 

218,975

 

 

 

166,767

 

Commitments and contingencies (Note 13)

 

 

 

 

 

 

 

Redeemable noncontrolling interest

 

22,095

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

Common shares, no par value; Authorized shares: unlimited;

   Issued and outstanding: 34,546 and 34,458, respectively

 

423,856

 

 

 

423,856

 

Additional paid-in capital

 

29,705

 

 

 

30,276

 

Accumulated deficit

 

(133,295

)

 

 

(167,547

)

Accumulated other comprehensive loss

 

(26,070

)

 

 

(27,715

)

Total stockholders' equity

 

294,196

 

 

 

258,870

 

Total liabilities, noncontrolling interest and stockholders’ equity

$

535,266

 

 

$

425,637

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

 

1


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands of U.S. dollars or shares, except per share amounts)

(Unaudited)

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Revenue

$

108,974

 

 

$

90,316

 

Cost of revenue

 

62,880

 

 

 

53,424

 

Gross profit

 

46,094

 

 

 

36,892

 

Operating expenses:

 

 

 

 

 

 

 

Research and development and engineering

 

9,215

 

 

 

8,052

 

Selling, general and administrative

 

23,001

 

 

 

21,187

 

Amortization of purchased intangible assets

 

2,849

 

 

 

2,108

 

Restructuring, acquisition and divestiture related costs

 

817

 

 

 

2,958

 

Total operating expenses

 

35,882

 

 

 

34,305

 

Operating income from continuing operations

 

10,212

 

 

 

2,587

 

Interest income (expense), net

 

(1,328

)

 

 

(1,185

)

Foreign exchange transaction gains (losses), net

 

(1

)

 

 

83

 

Other income (expense), net

 

96

 

 

 

743

 

Gain on acquisition of business

 

26,409

 

 

 

 

Income from continuing operations before income taxes

 

35,388

 

 

 

2,228

 

Income tax provision

 

1,114

 

 

 

322

 

Income from continuing operations

 

34,274

 

 

 

1,906

 

Loss from discontinued operations, net of tax

 

 

 

 

 

Consolidated net income

 

34,274

 

 

 

1,906

 

Less: Net income attributable to noncontrolling interest

 

(22

)

 

 

 

Net income attributable to Novanta Inc.

$

34,252

 

 

$

1,906

 

 

 

 

 

 

 

 

 

Earnings per common share from continuing operations:

 

 

 

 

 

 

 

Basic

$

0.99

 

 

$

0.05

 

Diluted

$

0.98

 

 

$

0.05

 

Loss per common share from discontinued operations:

 

 

 

 

 

 

 

Basic

$

 

 

$

 

Diluted

$

 

 

$

 

Earnings per common share attributable to Novanta Inc.:

 

 

 

 

 

 

 

Basic

$

0.99

 

 

$

0.05

 

Diluted

$

0.98

 

 

$

0.05

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding—basic

 

34,765

 

 

 

34,657

 

Weighted average common shares outstanding—diluted

 

35,125

 

 

 

34,853

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

 

2


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands of U.S. dollars)

(Unaudited)

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Consolidated net income

$

34,274

 

 

$

1,906

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

Foreign currency translation adjustments, net of tax (1)

 

1,440

 

 

 

65

 

Pension liability adjustments, net of tax (2)

 

205

 

 

 

449

 

Total other comprehensive income (loss)

 

1,645

 

 

 

514

 

Total consolidated comprehensive income (loss)

 

35,919

 

 

 

2,420

 

Less: Comprehensive income attributable to noncontrolling interest

 

(22

)

 

 

 

Comprehensive income (loss) attributable to Novanta Inc.

$

35,897

 

 

$

2,420

 

 

(1)  

The tax effect on this component of comprehensive income was nominal for all periods presented.

(2)  

The tax effect on this component of comprehensive income was nominal for all periods presented. See Note 4 for the total amount of pension liability adjustments reclassified out of accumulated other comprehensive income (loss).

The accompanying notes are an integral part of these consolidated financial statements.

 

 

 

3


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of U.S. dollars)

(Unaudited)

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Cash flows from operating activities:

 

 

 

 

 

 

 

Consolidated net income

$

34,274

 

 

$

1,906

 

Less: Loss from discontinued operations, net of tax

 

 

 

 

 

Income from continuing operations

 

34,274

 

 

 

1,906

 

Adjustments to reconcile income from continuing operations to

   net cash provided by operating activities of continuing operations:

 

 

 

 

 

 

 

Depreciation and amortization

 

6,482

 

 

 

5,229

 

Provision for inventory excess and obsolescence

 

549

 

 

 

1,493

 

Share-based compensation

 

1,469

 

 

 

1,342

 

Deferred income taxes

 

(1,607

)

 

 

108

 

Earnings from equity-method investment

 

(104

)

 

 

(740

)

Dividend from equity-method investment

 

 

 

 

2,341

 

Gain on acquisition of business

 

(26,409

)

 

 

 

Inventory acquisition fair value adjustment

 

1,035

 

 

 

 

Other

 

509

 

 

 

797

 

Changes in assets and liabilities which (used)/provided cash, excluding

   effects from businesses purchased or classified as discontinued operations:

 

 

 

 

 

 

 

Accounts receivable

 

(3,690

)

 

 

(1,139

)

Inventories

 

(4,414

)

 

 

(3,519

)

Prepaid income taxes, income taxes receivable, prepaid expenses and other current assets

 

(462

)

 

 

(514

)

Accounts payable, income taxes payable, accrued expenses

   and other current liabilities

 

4,851

 

 

 

1,302

 

Other non-current assets and liabilities

 

277

 

 

 

(308

)

Cash provided by operating activities of continuing operations

 

12,760

 

 

 

8,298

 

Cash provided by operating activities of discontinued operations

 

 

 

 

 

Cash provided by operating activities

 

12,760

 

 

 

8,298

 

Cash flows from investing activities:

 

 

 

 

 

 

 

Purchases of property, plant and equipment

 

(1,760

)

 

 

(2,341

)

Acquisition of businesses, net of cash acquired and working capital adjustments

 

(34,896

)

 

 

422

 

Proceeds from the sale of property, plant and equipment

 

 

 

 

3,589

 

Cash provided by (used in) investing activities of continuing operations

 

(36,656

)

 

 

1,670

 

Cash provided by investing activities of discontinued operations

 

 

 

 

1,498

 

Cash provided by (used in) investing activities

 

(36,656

)

 

 

3,168

 

Cash flows from financing activities:

 

 

 

 

 

 

 

Borrowings under revolving credit facility

 

42,000

 

 

 

 

Repayments of long-term debt and revolving credit facility

 

(1,875

)

 

 

(1,875

)

Payments of contingent considerations

 

(2,398

)

 

 

 

Repurchase of common stock

 

(370

)

 

 

 

Payments of withholding taxes from stock-based awards

 

(1,669

)

 

 

(1,320

)

Capital lease payments

 

(215

)

 

 

(342

)

Other financing activities

 

 

 

 

88

 

Cash provided by (used in) financing activities of continuing operations

 

35,473

 

 

 

(3,449

)

Cash provided by (used in) financing activities of discontinued operations

 

 

 

 

 

Cash provided by (used in) financing activities

 

35,473

 

 

 

(3,449

)

Effect of exchange rates on cash and cash equivalents

 

329

 

 

 

(84

)

Increase in cash and cash equivalents

 

11,906

 

 

 

7,933

 

Cash and cash equivalents, beginning of period

 

68,108

 

 

 

59,959

 

Cash and cash equivalents, end of period

$

80,014

 

 

$

67,892

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

Cash paid for interest

$

781

 

 

$

810

 

Cash paid for income taxes

$

1,819

 

 

$

2,470

 

Income tax refunds received

$

23

 

 

$

1

 

 

The accompanying notes are an integral part of these consolidated financial statements.  

 

 

 

4


 

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF MARCH 31, 2017

(Unaudited)

 

1. Basis of Presentation

Novanta Inc. and its subsidiaries (collectively referred to as the “Company”, “we”, “us”, “our”) is a global supplier of core technology solutions that give healthcare and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in photonics, vision and precision motion with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications.

The accompanying unaudited interim consolidated financial statements have been prepared in U.S. dollars and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), the instructions to Form 10-Q and the provisions of Regulation S-X pertaining to interim financial statements. Accordingly, certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. The interim consolidated financial statements and notes included in this report should be read in conjunction with the financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. In the opinion of management, these interim consolidated financial statements include all adjustments and accruals of a normal and recurring nature necessary to fairly state the results of the interim periods presented. The results for interim periods are not necessarily indicative of results to be expected for the full year or for any future periods.

Prior to January 10, 2017, the Company had an approximately 41% ownership interest in Laser Quantum Limited (“Laser Quantum”), a privately held company located in the United Kingdom, which was accounted for under the equity method of accounting. On January 10, 2017, the Company acquired an additional approximately 35% of the outstanding shares of Laser Quantum. As a result of this transaction, the Company’s ownership position in Laser Quantum increased from approximately 41% to approximately 76%. Since January 10, 2017, Laser Quantum has been consolidated in the Company’s consolidated financial statements.

The Company’s unaudited interim financial statements are prepared for each quarterly period ending on the Friday closest to the end of the calendar quarter, with the exception of the fourth quarter which always ends on December 31.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. The Company evaluates its estimates based on historical experience, current conditions and various other assumptions that it believes are reasonable under the circumstances. Estimates and assumptions are reviewed on an on-going basis and the effects of revisions are reflected in the period in which they are deemed to be necessary. Actual results could differ significantly from those estimates.

Recent Accounting Pronouncements

Presentation of Net Periodic Pension Cost

In March 2017, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2017-07, “Compensation – Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost,” which requires employers that offer or maintain defined benefit plans to disaggregate the service component from the other components of net benefit cost and provides guidance on the presentation of the service component and the other components of net benefit cost in the statement of operations. The new standard is effective for public companies for annual periods beginning after December 15, 2017. The Company expects to adopt the new standard in the first quarter of 2018 and expects to report its net periodic pension cost related to its frozen U.K. pension plan in Other income/(expense) in the consolidated statement of operations upon adoption.

Goodwill Impairment

5


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” which simplifies the accounting for goodwill impairment. The amendment in ASU 2017-04 removes Step-two of the goodwill impairment test, which requires a hypothetical purchase price allocation. ASU 2017-04 will become effective prospectively for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption p ermitted. The Company is currently evaluating the impact of the new standard on our consolidated financial statements.

Statement of Cash Flows Classification of Certain Cash Receipts and Cash Payments

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.” The standard further clarifies the classification in the cash flow statement of the following items: (i) debt prepayment or debt extinguishment costs; (ii) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (iii) contingent consideration payments made after a business combination; (iv) proceeds from the settlement of insurance claims; (v) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (vi) distributions received from equity method investees; (vii) beneficial interests in securitization transactions; and (viii) separately identifiable cash flows and application of the predominance principle. ASU 2016-15 will become effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early adoption permitted. ASU 2016-15 should be applied using a retrospective transition method for each period presented. The Company adopted ASU 2016-15 during the first quarter of 2017. The adoption of ASU 2016-15 resulted in ($2.4) million of payments of contingent considerations being reported as cash used in financing activities on the Company’s consolidated statements of cash flows for the three months ended March 31, 2017.

Leases

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” which provides comprehensive lease accounting guidance. The standard requires entities to recognize lease assets and liabilities on the balance sheet and to disclose key information about leasing arrangements. ASU 2016-02 will become effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of the new standard on our consolidated financial statements.

Revenue from Contracts with Customers

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606),” which provides guidance for revenue recognition. ASU 2014-09 supersedes the revenue recognition requirements in ASC 605, “Revenue Recognition” (Topic 605), and requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 will be effective for annual and interim reporting periods beginning after December 15, 2016. Early adoption is not permitted. Upon adoption, an entity may apply the new guidance either retrospectively to each prior reporting period presented or retrospectively only to customer contracts not yet completed as of the date of adoption with the cumulative effect of initially applying the standard recognized in beginning retained earnings at the date of the initial application. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers – Deferral of the Effective Date,” which defers the effective date of ASU 2014-09 by one year, with the option of early adoption as of the original effective date. The amendment in ASU 2015-14 will result in ASU 2014-09 being effective for annual and interim reporting periods beginning after December 15, 2017. The Company has identified various revenue streams that could be impacted by Topic 606 and has started to review individual customer contracts related to these various revenue streams to determine if any material differences exist between Topic 605 and Topic 606.  The Company will adopt Topic 606 in the first quarter of 2018 and has preliminarily concluded that it will use the modified retrospective method upon adoption.

 

 

2. Business Combinations

ThingMagic

On January 10, 2017, the Company acquired from Trimble Inc. certain assets and liabilities that constituted the business of ThingMagic, a Woburn, Massachusetts-based provider of ultra-high frequency (“UHF”) radio frequency identification (“RFID”) modules and finished RFID readers to OEMs in the medical and advanced industrial markets, for a total purchase price of $19.2 million, subject to customary working capital adjustments. The acquisition was financed with cash on hand and a $12.0 million draw-down on our revolving credit facility. The Company expects that the addition of ThingMagic will broaden its portfolio of RFID

6


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

soluti ons, while providing the resources to address the growing need for improvements in workflow solutions, patient safety, anti-counterfeiting, and asset tracking in a medical environment. ThingMagic is included in the Company’s Vision reportable segment.

The acquisition of ThingMagic has been accounted for as a business combination. The allocation of the purchase price is based upon a valuation of assets and liabilities acquired. Assets acquired and liabilities assumed have been recorded at their estimated fair values as of the acquisition date. The fair values of intangible assets were based on valuations using an income approach, with estimates and assumptions provided by management of ThingMagic and the Company. The process for estimating the fair values of identifiable intangible assets requires the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates. The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. The Company’s estimates and assumptions in determining the estimated fair values of certain assets and liabilities are subject to change within the measurement period (up to one year from the acquisition date) as a result of additional information obtained with regards to facts and circumstances that existed as of the acquisition date. The purchase price allocation is preliminary as the Company is in the process of collecting additional information for the valuation of inventory and intangible assets.

Based upon a preliminary valuation, the total purchase price was allocated as follows (in thousands):

 

 

Purchase Price

 

 

Allocation

 

Inventory

$

2,023

 

Intangible assets

 

7,283

 

Goodwill

 

9,976

 

Total assets acquired

 

19,282

 

 

 

 

 

Other liabilities

 

95

 

Total liabilities assumed

 

95

 

Total purchase price

$

19,187

 

The fair value of intangible assets is comprised of the following (dollar amounts in thousands):

 

 

 

 

 

 

Weighted Average

 

Estimated Fair

 

 

Amortization

 

Value

 

 

Period

Developed technologies

$

4,600

 

 

10 years

Customer relationships

 

2,380

 

 

10 years

Trademarks and trade names

 

303

 

 

5 years

Total

$

7,283

 

 

 

The purchase price allocation resulted in $7.3 million of identifiable intangible assets and $10.0 million of goodwill. As the ThingMagic acquisition is treated as an acquisition of assets for income tax purposes, the goodwill acquired is expected to be fully deductible. Intangible assets are being amortized over their weighted average useful lives primarily based upon the pattern in which anticipated economic benefits from such assets are expected to be realized. The goodwill recorded represents the anticipated incremental value of future cash flows potentially attributable to: (i) ThingMagic’s ability to grow its business with existing and new customers, including leveraging the Company’s customer base, (ii) cost synergies in combining the research and development capabilities from ThingMagic with the existing RFID capabilities within Novanta, and (iii) cost improvements due to the integration of ThingMagic operations into the Company’s existing infrastructure.

The operating results of ThingMagic were included in the Company’s results of operations beginning on January 10, 2017. ThingMagic contributed revenues of $1.9 million and a loss from continuing operations before income taxes of $0.3 million for the three months ended March 31, 2017. Operating loss from continuing operations before income taxes for the three months ended

7


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

March 31, 2017 included amortization of inventory fair value adjustments and amortization of purchased intangible assets of $0.6 million.

The pro forma financial information reflecting the operating results of ThingMagic, as if it had been acquired as of January 1, 2016, would not differ materially from the operating results of the Company as reported for the year ended December 31, 2016.

 

Laser Quantum Limited

On January 10, 2017, the Company acquired an additional approximately 35% of the outstanding shares of Laser Quantum, a Manchester, United Kingdom-based provider of solid state continuous wave lasers, femtosecond lasers, and optical light engines to OEMs in the medical market, for £25.5 million ($31.1 million) in cash consideration. The purchase price was financed with cash on hand and a $30.0 million draw-down on our revolving credit facility. By establishing control through a majority equity ownership, the Company expects to broaden its technology capability in photonics solutions for medical applications, particularly within the growing DNA sequencing market, while providing key enabling photonics-based technologies for instrumentation and life science applications such as biomedical imaging, cell sorting, and ophthalmology. Laser Quantum is included in the Company’s Photonics reportable segment.

As a result of this transaction, the Company’s ownership position in Laser Quantum increased from approximately 41% to approximately 76%. In connection with the purchase price allocation under the business combination rules, the Company recognized a nontaxable gain of $26.4 million in the consolidated statements of operations for the three months ended March 31, 2017. The gain represented the excess fair value of the Company’s previously-held equity interest in Laser Quantum over its carrying value.

The fair value of the approximately 41% equity interest previously held by the Company before the acquisition and the fair value of the approximately 24% noncontrolling interest (“NCI”) held by the remaining shareholders of Laser Quantum after the acquisition were determined using a combination of the discounted cash flow method (an income approach), the guideline public company method (a market approach), and the subject company transaction method (a market approach). The subject company transaction method was based on the purchase price paid by the Company for the acquisition of the additional approximately 35% of the outstanding shares, while giving consideration to the control and/or minority nature of the subject equity interests.

In addition, the Company and the remaining shareholders of Laser Quantum entered into a call and put option for the purchase and sale in 2020 of all remaining Laser Quantum shares held by the other shareholders, subject to certain conditions. The purchase price for the remaining shares will be based on a multiple of Laser Quantum’s EBITDA for the twelve months ending December 31, 2019, as defined in the call and put option agreement.

The acquisition of Laser Quantum has been accounted for as a business combination. The allocation of the purchase price is based upon a valuation of assets and liabilities acquired. Assets acquired and liabilities assumed have been recorded at their estimated fair values as of the acquisition date. The fair values of intangible assets were based on valuations using an income approach, with estimates and assumptions provided by management of Laser Quantum and the Company. The process for estimating the fair values of identifiable intangible assets requires the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates. The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. The Company’s estimates and assumptions in determining the estimated fair values of certain assets and liabilities are subject to change within the measurement period (up to one year from the acquisition date) as a result of additional information to be obtained with regards to facts and circumstances that existed as of the acquisition date. The purchase price allocation is preliminary as the Company is in the process of collecting additional information for the valuation of inventory, intangible assets, deferred tax liabilities, and unrecognized tax benefits.

Based upon a preliminary valuation, the total purchase price was allocated as follows (in thousands):

8


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

 

Purchase   Price

 

 

Allocation

 

Cash

$

15,343

 

Accounts receivable

 

2,739

 

Inventory

 

6,332

 

Property and equipment

 

1,700

 

Intangible assets

 

38,955

 

Goodwill

 

31,459

 

Other assets

 

717

 

Total fair value of assets

 

97,245

 

 

 

 

 

Accounts payable

 

796

 

Other liabilities

 

2,068

 

Deferred tax liabilities

 

7,110

 

Total fair value of liabilities

 

9,974

 

Total fair value of assets, net of fair value of liabilities

 

87,271

 

Less: fair value of equity interest previously held by Novanta

 

34,637

 

Less: fair value of noncontrolling interest

 

21,582

 

Total purchase price paid by Novanta

 

31,052

 

Less: cash acquired

 

15,343

 

Purchase price, net of cash acquired

$

15,709

 

 

The fair value of intangible assets is comprised of the following (dollar amounts in thousands):

 

 

 

 

 

 

Weighted Average

 

Estimated Fair

 

 

Amortization

 

Value

 

 

Period

Developed technologies

$

15,501

 

 

15 years

Customer relationships

 

19,990

 

 

15 years

Trademarks and trade names

 

1,964

 

 

15 years

Backlog

 

1,500

 

 

9 months

Total

$

38,955

 

 

 

The purchase price allocation resulted in $39.0 million of identifiable intangible assets and $31.5 million of goodwill. As the Laser Quantum acquisition is an acquisition of outstanding common shares, none of the resulting goodwill is deductible for tax purposes. Intangible assets are being amortized over their weighted average useful lives primarily based upon the pattern in which anticipated economic benefits from such assets are expected to be realized. The goodwill recorded represents the anticipated incremental value of future cash flow potential attributable to: (i) Laser Quantum’s ability to grow its business with existing and new customers, including leveraging the Company’s broader customer base, and (ii) cost improvements due to expansion in scale.

The operating results of Laser Quantum were included in the Company’s results of operations beginning on January 10, 2017. Laser Quantum contributed revenues of $7.2 million and income from continuing operations before income taxes of $0.1 million for the three months ended March 31, 2017. Operating income from continuing operations before income taxes for the three months ended March 31, 2017 included $2.1 million expenses associated with the amortization of inventory fair value step-up and purchased intangible assets.

The pro forma information for all periods presented below includes the effects of business combination accounting resulting from the acquisition of Laser Quantum, including amortization of inventory fair value adjustments, amortization of intangible assets, interest expense on borrowings in connection with the acquisition, elimination of the gain from business acquisition and income from equity method investment, and the related tax effects as though the acquisition had been consummated as of January 1, 2016. The pro forma financial information is presented for comparative purposes only and is not necessarily indicative of the results of operations that actually would have been achieved if the acquisition had taken place on January 1, 2016.

9


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Revenue

$

109,740

 

 

$

97,015

 

Income from continuing operations

$

8,017

 

 

$

2,257

 

Earnings per share from continuing operations - Basic

$

0.23

 

 

$

0.06

 

Earnings per share from continuing operations - Diluted

$

0.23

 

 

$

0.06

 

 

Acquisition Costs

Acquisition-related costs are included in restructuring, acquisition and divestiture related costs in the consolidated statements of operations. Acquisition-related costs for ThingMagic and Laser Quantum are as follows (in thousands):

 

 

Three   Months Ended

 

 

March 31,

 

 

2017

 

ThingMagic

$

149

 

Laser Quantum

$

264

 

 

 

 

3. Discontinued Operations and Divestitures

In July 2014, the Company completed the sale of certain assets and liabilities of its Scientific Lasers business for approximately $6.5 million in cash, net of working capital adjustments.  In accordance with the purchase and sale agreement, $1.5 million of the sales proceeds was held in escrow until January 2016. In January 2016, the $1.5 million escrow was released to the Company in full and is reported as cash flow from investing activities of discontinued operations.

 

 

4. Accumulated Other Comprehensive Income (Loss)

Changes in accumulated other comprehensive income (loss) was as follows (in thousands):

 

 

Total accumulated

 

 

 

 

 

 

 

 

 

 

other

 

 

Foreign currency

 

 

 

 

 

 

comprehensive

 

 

translation

 

 

Pension

 

 

income (loss)

 

 

adjustments

 

 

liabilities

 

Balance at December 31, 2016

$

(27,715

)

 

$

(17,222

)

 

$

(10,493

)

Other comprehensive income (loss)

 

1,358

 

 

 

1,440

 

 

 

(82

)

Amounts reclassified from other comprehensive

   income (loss)  (1)

 

287

 

 

 

 

 

 

287

 

Balance at March 31, 2017

$

(26,070

)

 

$

(15,782

)

 

$

(10,288

)

 

 

(1)

The amounts reclassified from other comprehensive income (loss) were included in selling, general and administrative expenses in the consolidated statements of operations.

 

 

5. Earnings per Share

Basic earnings per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. For diluted earnings per common share, the denominator also includes the dilutive effect of outstanding restricted stock units, stock options and total shareholder return performance restricted stock units determined using the treasury stock method. Dilutive effects of contingently issuable shares are included in the weighted average dilutive share calculation using the

10


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

treasury stock method when the contingencies have been resolved. For periods in which net losses are generated, the dilutive potential common shares are excluded from the calculation of diluted earnings per share as the effect would be anti-dilutive.

The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share amounts):

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Numerators:

 

 

 

 

 

 

 

Income from continuing operations

$

34,274

 

 

$

1,906

 

Less: Net income attributable to noncontrolling interest

 

(22

)

 

 

 

Income from continuing operations attributable to Novanta Inc.

 

34,252

 

 

 

1,906

 

Loss from discontinued operations

 

 

 

 

 

Net income attributable to Novanta Inc.

$

34,252

 

 

$

1,906

 

 

 

 

 

 

 

 

 

Denominators:

 

 

 

 

 

 

 

Weighted average common shares outstanding— basic

 

34,765

 

 

 

34,657

 

Dilutive potential common shares

 

360

 

 

 

196

 

Weighted average common shares outstanding— diluted

 

35,125

 

 

 

34,853

 

Antidilutive common shares excluded from above

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic Earnings per Share:

 

 

 

 

 

 

 

From continuing operations

$

0.99

 

 

$

0.05

 

From discontinued operations

$

 

 

$

 

Basic earnings per share attributable to Novanta Inc.

$

0.99

 

 

$

0.05

 

 

 

 

 

 

 

 

 

Diluted Earnings per Share:

 

 

 

 

 

 

 

From continuing operations

$

0.98

 

 

$

0.05

 

From discontinued operations

$

 

 

$

 

Diluted earnings per share attributable to Novanta Inc.

$

0.98

 

 

$

0.05

 

 

Common Share Repurchases

During the three months ended March 31, 2017, the Company repurchased 14,000 shares in the open market for an aggregate purchase price of $0.4 million at an average price of $26.41 per share.

 

 

6. Fair Value Measurements

ASC 820, “Fair Value Measurements,” establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the third is considered unobservable:

 

Level 1: Quoted prices for identical assets or liabilities in active markets which the Company can access.

 

Level 2: Observable inputs other than those described in Level 1.

 

Level 3: Unobservable inputs.

The Company’s cash equivalents are investments in money market accounts, which represent the only asset the Company measures at fair value on a recurring basis. The Company determines the fair value of cash equivalents using a market approach based on quoted prices in active markets. The fair values of cash, accounts receivable, income taxes receivable, accounts payable, income taxes payable and accrued expenses and other current liabilities (excluding contingent considerations) approximate their carrying values because of their short-term nature.

11


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

Contingent consideration

On December 18, 2015, the Company acquired all assets and certain liabilities of Skyetek. Under the purchase and sale agreement for the Skyetek acquisition, the owners of Skyetek are eligible to receive contingent consideration based on the achievement of certain sales order commitment targets from October 2015 through June 2017. The undiscounted range of possible contingent consideration is zero to $0.3 million. If such targets are achieved, the contingent consideration will be payable in 2017. The Company recognized an estimated fair value of $0.2 million as part of the purchase price as of the acquisition date. Subsequent changes in the estimated fair value of this contingent liability will be recorded in the consolidated statement of operations in restructuring, acquisition and divestiture related costs until the liability is fully settled. There have been no changes to the fair value of the contingent consideration since the acquisition date.

On November 11, 2015, the Company acquired Lincoln Laser. Under the purchase and sale agreement for the Lincoln Laser acquisition, the shareholders of Lincoln Laser are eligible to receive contingent consideration based on the achievement of certain revenue targets for fiscal year 2016. The estimated fair value of the contingent consideration of $2.3 million was determined based on the Monte Carlo valuation method and was recorded as part of the purchase price as of the acquisition date. Based on Lincoln Laser’s fiscal year 2016 revenue results, the fair value of the contingent consideration for Lincoln Laser was adjusted to $1.4 million as of December 31, 2016. The Company paid $1.4 million as final settlement of the contingent consideration during the three months ended March 31, 2017.

On February 19, 2015, the Company acquired Applimotion. Under the purchase and sale agreement for the Applimotion acquisition, the former shareholders of Applimotion are eligible to receive contingent consideration based on the achievement of certain revenue targets for fiscal years 2015 to 2017. The undiscounted range of contingent considerations is zero to $4.0 million. If such targets are achieved, the contingent consideration will be payable in cash in two installments in 2017 and 2018, respectively. The estimated fair value of the contingent consideration of $1.0 million was determined based on the Monte Carlo valuation method and was recorded as part of the purchase price as of the acquisition date. Subsequent changes in the estimated fair value of this contingent liability are recorded in the consolidated statement of operations in restructuring, acquisition and divestiture related costs until the liability is fully settled. Under the Monte Carlo valuation method, the fair value of the contingent consideration for Applimotion was $3.6 million as of December 31, 2016. Based on Applimotion’s revenue performance for 2015 and 2016, the Company paid $1.2 million contingent consideration during the three months ended March 31, 2017. The estimated fair value of the remaining contingent consideration of $2.4 million is reported as a current liability in accrued expenses and other current liabilities on the consolidated balance sheet as of March 31, 2017. The second installment of the contingent consideration will be payable in the first quarter of 2018.

The following table summarizes the fair values of our financial assets and liabilities as of March 31, 2017 (in thousands):

 

 

 

 

 

 

Quoted Prices in

 

 

 

 

 

 

Significant Other

 

 

 

 

 

 

Active Markets for

 

 

Significant Other

 

 

Unobservable

 

 

 

 

 

 

Identical Assets

 

 

Observable Inputs

 

 

Inputs

 

 

Fair Value

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

$

1,881

 

 

$

1,881

 

 

$

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contingent consideration - Current

$

2,531

 

 

$

 

 

$

 

 

$

2,531

 

Contingent consideration - Long-term

 

 

 

 

 

 

 

 

 

 

 

 

$

2,531

 

 

$

 

 

$

 

 

$

2,531

 

 

12


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

The following table summarizes the fair values of our financial assets and liabilities as of December 31, 201 6 (in thousands):

 

 

 

 

 

 

Quoted Prices in

 

 

 

 

 

 

Significant Other

 

 

 

 

 

 

Active Markets for

 

 

Significant Other

 

 

Unobservable

 

 

 

 

 

 

Identical Assets

 

 

Observable Inputs

 

 

Inputs

 

 

Fair Value

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

$

9,569

 

 

$

9,569

 

 

$

 

 

$

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contingent consideration - Current

$

2,775

 

 

$

 

 

$

 

 

$

2,775

 

Contingent consideration - Long-term

 

2,381

 

 

 

 

 

 

 

 

 

2,381

 

 

$

5,156

 

 

$

 

 

$

 

 

$

5,156

 

 

Changes in the fair value of Level 3 contingent consideration during the three months ended March 31, 2017 were as follows (in thousands):

 

 

Contingent Consideration

 

Balance at December 31, 2016

$

5,156

 

Payment to Applimotion

 

(1,192

)

Payment to Lincoln Laser

 

(1,433

)

Balance at March 31, 2017

$

2,531

 

 

See Note 9 to Consolidated Financial Statements for a discussion of the estimated fair value of the Company’s outstanding debt.

 

 

7. Goodwill and Intangible Assets

Goodwill

Goodwill is recorded when the consideration for a business combination exceeds the fair value of net tangible and identifiable intangible assets acquired. The Company tests its goodwill balances annually for impairment as of the beginning of the second quarter or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. The Company performed its last annual goodwill impairment test at the beginning of the second quarter of 2016 and noted no impairment of goodwill. Implied fair value of all reporting units exceeded their carrying values by at least 20%.

The following table summarizes changes in goodwill during the three months ended March 31, 2017 (in thousands):

 

Balance at beginning of the period

$

108,128

 

Goodwill acquired from Laser Quantum acquisition

 

31,459

 

Goodwill acquired from ThingMagic acquisition

 

9,976

 

Effect of foreign exchange rate changes

 

715

 

Balance at end of the period

$

150,278

 

 

Goodwill by reportable segment as of March 31, 2017 was as follows (in thousands):

 

 

Reportable Segment

 

 

 

 

 

 

Photonics

 

 

Vision

 

 

Precision

Motion

 

 

Total

 

Goodwill

$

168,452

 

 

$

99,092

 

 

$

33,963

 

 

$

301,507

 

Accumulated impairment of goodwill

 

(102,461

)

 

 

(31,722

)

 

 

(17,046

)

 

 

(151,229

)

Total

$

65,991

 

 

$

67,370

 

 

$

16,917

 

 

$

150,278

 

 

13


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

Goodwill by reportable segment as of December 31, 201 6 was as follows (in thousands):

 

 

Reportable Segment

 

 

 

 

 

 

Photonics

 

 

Vision

 

 

Precision

Motion

 

 

Total

 

Goodwill

$

136,278

 

 

$

89,116

 

 

$

33,963

 

 

$

259,357

 

Accumulated impairment of goodwill

 

(102,461

)

 

 

(31,722

)

 

 

(17,046

)

 

 

(151,229

)

Total

$

33,817

 

 

$

57,394

 

 

$

16,917

 

 

$

108,128

 

 

Intangible Assets

Intangible assets as of March 31, 2017 and December 31, 2016, respectively, are summarized as follows (in thousands):

 

 

March 31, 2017

 

 

December 31, 2016

 

 

Gross Carrying

Amount

 

 

Accumulated

Amortization

 

 

Net Carrying

Amount

 

 

Gross Carrying

Amount

 

 

Accumulated

Amortization

 

 

Net Carrying

Amount

 

Amortizable intangible assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Patents and acquired technologies

$

105,232

 

 

$

(69,585

)

 

$

35,647

 

 

$

84,742

 

 

$

(67,902

)

 

$

16,840

 

Customer relationships

 

92,393

 

 

 

(44,892

)

 

 

47,501

 

 

 

69,554

 

 

 

(42,934

)

 

 

26,620

 

Customer backlog

 

2,156

 

 

 

(1,101

)

 

 

1,055

 

 

 

622

 

 

 

(540

)

 

 

82

 

Non-compete covenant

 

2,514

 

 

 

(1,553

)

 

 

961

 

 

 

2,514

 

 

 

(1,419

)

 

 

1,095

 

Trademarks and trade names

 

13,030

 

 

 

(6,858

)

 

 

6,172

 

 

 

10,709

 

 

 

(6,630

)

 

 

4,079

 

Amortizable intangible assets

 

215,325

 

 

 

(123,989

)

 

 

91,336

 

 

 

168,141

 

 

 

(119,425

)

 

 

48,716

 

Non-amortizable intangible assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade names

 

13,027

 

 

 

 

 

 

13,027

 

 

 

13,027

 

 

 

 

 

 

13,027

 

Totals

$

228,352

 

 

$

(123,989

)

 

$

104,363

 

 

$

181,168

 

 

$

(119,425

)

 

$

61,743

 

 

All definite-lived intangible assets are amortized either on a straight-line basis or an economic benefit basis over their remaining useful life. Amortization expense for customer relationships and definite-lived trademarks, trade names and other intangibles is included in operating expenses in the accompanying consolidated statements of operations. Amortization expense for patents and acquired technologies is included in cost of revenue in the accompanying consolidated statements of operations. Amortization expense is as follows (in thousands):

 

 

Three Months Ended

 

 

March 31,

2017

 

 

April 1,

2016

 

Amortization expense – cost of revenue

$

1,641

 

 

$

1,184

 

Amortization expense – operating expenses

 

2,849

 

 

 

2,108

 

Total amortization expense

$

4,490

 

 

$

3,292

 

 

Estimated amortization expense for each of the five succeeding years and thereafter as of March 31, 2017 was as follows (in thousands):

 

Year Ending December 31,

 

Cost of Revenue

 

 

Operating

Expenses

 

 

Total

 

2017(remainder of year)

 

$

4,943

 

 

$

7,946

 

 

$

12,889

 

2018

 

 

5,088

 

 

 

9,417

 

 

 

14,505

 

2019

 

 

4,605

 

 

 

7,327

 

 

 

11,932

 

2020

 

 

4,125

 

 

 

5,251

 

 

 

9,376

 

2021

 

 

3,664

 

 

 

4,739

 

 

 

8,403

 

Thereafter

 

 

13,222

 

 

 

21,009

 

 

 

34,231

 

Total

 

$

35,647

 

 

$

55,689

 

 

$

91,336

 

 

14


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

 

8. Supplementary Balance Sheet Information

The following tables provide the details of selected balance sheet items as of the periods indicated (in thousands):

Inventories

 

 

March 31,

 

 

December 31,

 

 

2017

 

 

2016

 

Raw materials

$

43,457

 

 

$

39,822

 

Work-in-process

 

10,218

 

 

 

8,012

 

Finished goods

 

14,217

 

 

 

9,511

 

Demo and consigned inventory

 

3,127

 

 

 

2,400

 

Total inventories

$

71,019

 

 

$

59,745

 

 

Accrued Expenses and Other Current Liabilities

 

 

March 31,

 

 

December 31,

 

 

2017

 

 

2016

 

Accrued compensation and benefits

$

11,666

 

 

$

9,647

 

Accrued warranty

 

3,925

 

 

 

3,142

 

Accrued restructuring

 

1,032

 

 

 

1,371

 

Accrued professional services

 

1,271

 

 

 

1,237

 

Accrued contingent considerations

 

2,531

 

 

 

2,775

 

Customer deposits

 

1,904

 

 

 

1,164

 

Other

 

8,612

 

 

 

7,612

 

Total

$

30,941

 

 

$

26,948

 

 

Accrued Warranty

 

 

Three Months Ended

 

 

March 31,

2017

 

 

April 1,

2016

 

Balance at beginning of the period

$

3,142

 

 

$

3,335

 

Provision charged to cost of revenue

 

799

 

 

 

310

 

Acquisition related warranty accrual

 

419

 

 

 

 

Use of provision

 

(442

)

 

 

(393

)

Foreign currency exchange rate changes

 

7

 

 

 

(4

)

Balance at end of period

$

3,925

 

 

$

3,248

 

 

Other Long Term Liabilities

 

 

March 31,

 

 

December 31,

 

 

2017

 

 

2016

 

Capital lease obligations

$

8,007

 

 

$

8,111

 

Accrued pension liabilities

 

5,711

 

 

 

5,957

 

Accrued contingent considerations

 

 

 

 

2,381

 

Other

 

2,150

 

 

 

2,264

 

Total

$

15,868

 

 

$

18,713

 

 

 

15


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

9. Debt

Debt consisted of the following (in thousands):

 

 

March 31,

 

 

December 31,

 

 

2017

 

 

2016

 

Senior Credit Facilities – term loan

$

7,500

 

 

$

7,500

 

Less: unamortized debt issuance costs

 

(132

)

 

 

(134

)

Total current portion of long-term debt

$

7,368

 

 

$

7,366

 

 

 

 

 

 

 

 

 

Senior Credit Facilities – term loan

$

61,875

 

 

$

63,750

 

Senior Credit Facilities – revolving credit facility

 

52,000

 

 

 

10,000

 

Less: unamortized debt issuance costs

 

(3,010

)

 

 

(3,196

)

Total long-term debt

$

110,865

 

 

$

70,554

 

 

 

 

 

 

 

 

 

Total Senior Credit Facilities

$

118,233

 

 

$

77,920

 

 

Senior Credit Facilities

On May 19, 2016, the Company entered into the second amended and restated credit agreement (the “Second Amended and Restated Credit Agreement”) with new and existing lenders for an aggregate credit facility of $300.0 million, consisting of a $75.0 million, 5-year term loan facility due in quarterly installments of $1.9 million beginning in July 2016 and a $225.0 million, 5-year revolving credit facility (collectively, the “Senior Credit Facilities”). The Senior Credit Facilities mature in May 2021. Quarterly installments due in the next twelve months under the term loan amount to $7.5 million and are classified as a current liability on the consolidated balance sheet. The increase in the amount outstanding under the Company’s revolving credit facility in the three months ended March 31, 2017 was related to additional borrowings to fund the Laser Quantum and ThingMagic acquisitions.

The Company is required to satisfy certain financial and non-financial covenants under the Second Amended and Restated Credit Agreement. The Company was in compliance with these covenants as of March 31, 2017.

Liens

The Company’s obligations under the Senior Credit Facilities are secured on a senior basis by a lien on substantially all of the assets of the Company and its material United States (“U.S.”) and United Kingdom (“U.K.”) subsidiaries and guaranteed by the Company and its material U.S. and U.K. subsidiaries. The Second Amended and Restated Credit Agreement also contains customary events of default.

Fair Value of Debt

As of March 31, 2017 and December 31, 2016, the outstanding balance of the Company’s debt approximated its fair value based on current rates available to the Company for debt of the same maturity.

 

10. Share-based Compensation

The table below summarizes share-based compensation expense recorded in income from continuing operations in the consolidated statements of operations (in thousands):

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Selling, general and administrative

$

1,358

 

 

$

1,243

 

Research and development and engineering

 

43

 

 

 

25

 

Cost of revenue

 

68

 

 

 

74

 

Total share-based compensation expense

$

1,469

 

 

$

1,342

 

16


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

 

The expense recorded during each of the three-month periods ended March 31, 2017 and April 1, 2016, respectively, included $0.5 million related to deferred stock units granted to the members of the Company’s Board of Directors.

Service-based Restricted Stock Units and Deferred Stock Units

The Company’s restricted stock units (“RSUs”) have been issued with vesting periods of three, four, and five years and vest based solely on service conditions. Accordingly, the Company recognizes compensation expense on a straight-line basis over the requisite service period. The Company reduces the compensation expense by an estimated forfeiture rate which is based on anticipated forfeitures and actual experience.

Deferred stock units (“DSUs”) are granted solely to the members of the Company’s Board of Directors, and have been issued as fully vested and non-forfeitable awards upon grant. The compensation expense associated with the DSUs is recognized in full on the respective date of grant.

The table below summarizes activities relating to RSUs and DSUs issued and outstanding under the Company’s Amended and Restated 2010 Incentive Plan during the three months ended March 31, 2017:

 

 

Shares

(In thousands)

 

 

Weighted

Average Grant

Date Fair Value

 

Unvested at December 31, 2016

 

635

 

 

$

13.97

 

Granted

 

220

 

 

$

24.00

 

Vested

 

(189

)

 

$

13.87

 

Forfeited

 

(1

)

 

$

16.52

 

Unvested at March 31, 2017

 

665

 

 

$

17.32

 

Expected to vest as of March 31, 2017

 

614

 

 

 

 

 

 

The total fair value of RSUs and DSUs that vested during the three months ended March 31, 2017 was $4.7 million based on the market price of the underlying stock on the date of vesting.

Performance-based Awards

The Company granted two types of performance-based awards to certain members of the executive management team: non-GAAP EPS performance-based restricted stock units (“EPS-PSUs”) and relative total shareholder return performance-based restricted stock units (“TSR-PSUs”). Both types of performance-based restricted stock units generally cliff vest on the first day following the end of the three-year performance period.

The number of common shares to be issued upon settlement following vesting of the EPS-PSUs is determined based on the Company’s cumulative non-GAAP EPS over the three-year performance period against the target established by the Company’s Board of Directors at the time of grant and will be in the range of zero to 200% of the target number of shares. The Company recognizes the related compensation expense ratably over the performance period based on the number of shares that are deemed probable of vesting at the end of the three-year performance cycle. This probability assessment is performed quarterly and the cumulative effect of a change in the estimated compensation expense, if any, is recognized in the consolidated statement of operations in the period in which such determination is made.  

The number of shares to be issued upon settlement following vesting of the TSR-PSUs is determined based on the relative market performance of the Company’s common stock compared to the Russell 2000 Index over the three-year performance period using a payout formula established by the Company’s Board of Directors at the time of grant and will be in the range of zero to 200% of the target number of shares. The Company recognizes the related compensation expense based on the fair value of the TSR-PSUs, determined using the Monte-Carlo valuation model as of the date of grant, on a straight-line basis from the grant date to the end of the three-year performance period. Compensation expense will not be affected by the number of TSR-PSUs that will actually vest at the end of the three-year performance period.

17


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

The table below summarizes the activities relating to the performance-based awards issued and outstanding under the Company’s Amended and Restated 2010 Incentive Plan during the three months ended March 31, 2017 :

 

 

Shares

(In thousands)

 

 

Weighted

Average Grant

Date Fair Value

 

Unvested at December 31, 2016

 

29

 

 

$

14.13

 

Granted

 

60

 

 

$

28.81

 

Vested

 

 

 

$

 

Forfeited

 

 

 

$

 

Unvested at March 31, 2017

 

89

 

 

$

24.00

 

 

The fair value of the TSR-PSUs at the date of grant was estimated using the Monte-Carlo valuation model with the following assumptions:

 

Three Months Ended March 31, 2017

 

Grant-date stock price

$

24.30

 

Expected volatility

 

28.6

%

Risk-free interest rate

 

1.44

%

Expected annual dividend yield

 

 

Weighted average fair value

$

33.31

 

 

Stock Options

The fair value of stock options is estimated using the Black-Scholes valuation model. Key input assumptions include the expected option term, the expected volatility of the common stock over the expected term of the options, the risk-free interest rate, and the expected dividend yield. Compensation expense related to stock options is recognized in the consolidated statement of operations on a straight-line basis over the vesting period. No stock options were granted during the three months ended March 31, 2017.

 

 

11. Income Taxes

The Company determines its estimated annual effective tax rate at the end of each interim period based on full-year forecasted pre-tax income and facts known at that time. The estimated annual effective tax rate is applied to the year-to-date pre-tax income at the end of each interim period. The tax effect of significant unusual items is reflected in the period in which they occur. Since the Company is incorporated in Canada, it is required to use Canada’s statutory tax rate of 29.0% in the determination of the estimated annual effective tax rate.

The Company’s effective tax rate on income from continuing operations of 3.1% for the three months ended March 31, 2017 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, the impact associated with establishing control over Laser Quantum upon the acquisition of an additional 35% of Laser Quantum’s outstanding shares, losses in jurisdictions with a full valuation allowance, and other discrete items for the period.  The Company reported a nontaxable gain of $26.4 million on its previously-held Laser Quantum equity interest and wrote off $1.4 million of Laser Quantum related deferred tax liability, which had a combined 24.5% favorable impact on our effective tax rate for the three months ended March 31, 2017.

The Company’s effective tax rate on income from continuing operations of 14.5% for the three months ended April 1, 2016 differed from the Canadian statutory rate of 27.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, losses in jurisdictions with a full valuation allowance, the Laser Quantum dividend distribution and the impact of other discrete items for the period. The Company received a tax free cash dividend of $2.3 million from Laser Quantum, which had an 18.9% favorable impact on our effective tax rate for the three months ended April 1, 2016.

The Company maintains a valuation allowance on some of its deferred tax assets in certain jurisdictions. A valuation allowance is required when, based upon an assessment of various factors, including recent operating loss history, anticipated future earnings, and

18


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

prudent and reasonable tax planning strategies, it is more likely than not that some portion of the deferred tax assets will not be realized.

 

 

12. Restructuring, Acquisition and Divestiture Related Costs

The following table summarizes restructuring, acquisition and divestiture related costs in the accompanying consolidated statements of operations (in thousands):

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

2016 restructuring

$

33

 

 

$

2,500

 

2011 restructuring

 

4

 

 

 

212

 

Total restructuring and divestiture charges

 

37

 

 

 

2,712

 

Acquisition and related charges

 

780

 

 

 

246

 

Total restructuring, acquisition and divestiture related costs

$

817

 

 

$

2,958

 

 

2016 Restructuring

During the third quarter of 2015, the Company initiated the 2016 restructuring program, which included consolidating certain of our manufacturing operations to optimize our facility footprint and better utilize resources, costs associated with discontinuing our radiology product line and reducing redundant costs due to productivity cost savings and business volume reductions. We substantially completed the 2016 restructuring program during the second quarter of 2016. As of March 31, 2017, the Company incurred cumulative costs related to this restructuring plan totaling $6.2 million. The Company expects to incur additional restructuring charges of $0.2 million to $0.3 million related to the 2016 restructuring plan.

The following table summarizes restructuring costs for each segment and unallocated corporate and shared services related to the 2016 restructuring plan (in thousands):

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Photonics

$

 

 

$

469

 

Vision

 

32

 

 

 

1,739

 

Precision Motion

 

 

 

 

87

 

Unallocated Corporate and Shared Services

 

1

 

 

 

205

 

Total

$

33

 

 

$

2,500

 

2011 Restructuring

In November 2011, the Company announced a strategic initiative (“2011 restructuring”), which aimed to consolidate operations to reduce the Company’s cost structure and improve operational efficiency. As part of this initiative, the Company eliminated facilities through the consolidation of certain manufacturing, sales and distribution facilities and the exit of Semiconductor Systems and Laser Systems businesses. The Company substantially completed the 2011 restructuring program by the end of 2013. In March 2016, the Company sold its previously exited Laser Systems facility located in Orlando, Florida for cash at the net carrying value of $3.5 million. In December 2016, the lease agreement for the Company’s previously exited laser scanner business facility was terminated.

19


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

Rollforward of Accrued Expenses Related to Restructuring

The following table summarizes the accrual activities, by component, related to the Company’s restructuring plans recorded in the accompanying consolidated balance sheets (in thousands):

 

 

Total

 

 

Severance

 

 

Facility

 

 

Depreciation

 

 

Other

 

Balance at December 31, 2016

$

1,736

 

 

$

611

 

 

$

1,111

 

 

$

 

 

$

14

 

Restructuring charges

 

37

 

 

 

32

 

 

 

 

 

 

 

 

 

5

 

Cash payments

 

(420

)

 

 

(281

)

 

 

(125

)

 

 

 

 

 

(14

)

Non-cash write-offs and other adjustments

 

 

 

 

8

 

 

 

(8

)

 

 

 

 

 

 

Balance at March 31, 2017

$

1,353

 

 

$

370

 

 

$

978

 

 

$

 

 

$

5

 

Acquisition and Related Charges

Acquisition related costs incurred to effect a business combination, including finders’ fees, legal, valuation, and other professional or consulting fees, totaled $0.8 million and $0.3 million for the three months ended March 31, 2017 and April 1, 2016, respectively.

 

13. Commitments and Contingencies

Leases

The Company leases certain equipment and facilities under operating and capital lease agreements. There have been no material changes to the Company’s leases through March 31, 2017 from those discussed in Note 15 to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.  

Purchase Commitments

There have been no material changes to the Company’s purchase commitments since December 31, 2016.  

Legal Contingencies

The Company is subject to various legal proceedings and claims that arise in the ordinary course of business. The Company does not believe that the outcome of these claims will have a material adverse effect upon its consolidated financial statements but there can be no assurance that any such claims, or any similar claims, would not have a material adverse effect upon its consolidated financial statements.

Guarantees and Indemnifications

In the normal course of its operations, the Company executes agreements that provide for indemnification and guarantees to counterparties in transactions such as business dispositions, sale of assets, sale of products and operating leases. Additionally, the by-laws of the Company require it to indemnify certain current or former directors, officers, and employees of the Company against expenses incurred by them in connection with each proceeding in which he or she is involved as a result of serving or having served in certain capacities. Indemnification is not available with respect to a proceeding as to which it has been adjudicated that the person did not act in good faith in the reasonable belief that the action was in the best interests of the Company. Certain of the officers and directors are also a party to indemnification agreements with the Company. These indemnification agreements provide, among other things, that the director and officer shall be indemnified to the fullest extent permitted by applicable law against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such officer or director in connection with any proceeding by reason of his or her relationship with the Company. In addition, the indemnification agreements provide for the advancement of expenses incurred by such director or officer in connection with any proceeding covered by the indemnification agreement, subject to the conditions set forth therein and to the extent such advancement is not prohibited by law. The indemnification agreements also set out the procedures for determining entitlement to indemnification, the requirements relating to notice and defense of claims for which indemnification is sought, the procedures for enforcement of indemnification rights, the limitations on and exclusions from indemnification, and the minimum levels of directors’ and officers’ liability insurance to be maintained by the Company.

20


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

 

14. Redeemable Noncontrolling Interest

As a result of the Company’s acquisition of additional outstanding shares of Laser Quantum from the remaining shareholders on January 10, 2017, the Company increased its ownership position in Laser Quantum from approximately 41% to approximately 76% and began to consolidate the operating results of Laser Quantum in the consolidated financial statements. As part of the purchase agreement, the Company and the remaining equity holders entered into a call and put option agreement for the purchase and sale in 2020 of all remaining Laser Quantum shares held by the remaining equity holders, subject to certain conditions. The purchase price for the remaining shares will be based on a multiple of Laser Quantum’s EBITDA for the twelve months ending December 31, 2019, as defined in the call and put option agreement. As a result of the put option, the noncontrolling interest is considered a redeemable equity instrument and is presented as temporary equity on the consolidated balance sheet as of March 31, 2017. The proportionate share of the net income from Laser Quantum attributable to the noncontrolling interest has been reported as a reduction to the consolidated net income in the Company’s consolidated statements of operations.

The initial value of the noncontrolling interest of £17.7 million ($21.6 million) was measured at fair value at the date of the acquisition and will be adjusted to its redemption value on a quarterly basis, to the extent that the redemption value exceeds the carrying value of the noncontrolling interest. The fair value of the noncontrolling interest was determined using a combination of the discounted cash flow method (an income approach), the guideline public company method (a market approach), and the subject company transaction method (a market approach).

 

15. Segment Information

The Company evaluates the performance of, and allocates resources to, its segments based on revenue, gross profit and operating profit. The Company’s reportable segments have been identified based on commonality and adjacency of technologies, applications and customers amongst the Company’s individual product lines.

The Company operates in three reportable segments: Photonics, Vision, and Precision Motion. The reportable segments and their principal activities consist of the following:

Photonics

The Photonics segment designs, manufactures and markets photonics-based solutions, including CO2 lasers, continuous wave and femtosecond lasers, optical light engines, and laser scanning and laser beam delivery products, to customers worldwide. The segment serves highly demanding photonics-based applications such as industrial material processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The vast majority of the segment’s product offerings are sold to Original Equipment Manufacturers (“OEMs”) customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

Vision

The Vision segment designs, manufactures and markets a range of medical grade technologies, including visualization solutions, imaging informatics products, optical data collection and machine vision technologies, RFID technologies, thermal printers, light and color measurement instrumentation, and embedded touch screen solutions, to customers worldwide. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

Precision Motion

The Precision Motion segment designs, manufactures and markets optical encoders, precision motor and motion control technology, air bearing spindles and precision machined components to customers worldwide. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

21


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF MARCH 31, 2017

(Unaudited)

 

Reportable Segment Financial Information

Revenue, gross profit, gross profit margin, operating income (loss) from continuing operations, and depreciation and amortization by reportable segments are as follows (in thousands):

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Revenue

 

 

 

 

 

 

 

Photonics

$

50,736

 

 

$

40,358

 

Vision

 

32,762

 

 

 

28,862

 

Precision Motion

 

25,476

 

 

 

21,096

 

Total

$

108,974

 

 

$

90,316

 

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Gross Profit

 

 

 

 

 

 

 

Photonics

$

21,789

 

 

$

17,997

 

Vision

 

13,146

 

 

 

9,579

 

Precision Motion

 

11,518

 

 

 

9,668

 

Unallocated Corporate and Shared Services

 

(359

)

 

 

(352

)

Total

$

46,094

 

 

$

36,892

 

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Gross Profit Margin

 

 

 

 

 

 

 

Photonics

 

42.9

%

 

 

44.6

%

Vision

 

40.1

%

 

 

33.2

%

Precision Motion

 

45.2

%

 

 

45.8

%

Total

 

42.3

%

 

 

40.8

%

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Operating Income (Loss) from Continuing Operations

 

 

 

 

 

 

 

Photonics

$

8,080

 

 

$

6,856

 

Vision

 

1,525

 

 

 

(3,771

)

Precision Motion

 

7,164

 

 

 

5,235

 

Unallocated Corporate and Shared Services

 

(6,557

)

 

 

(5,733

)

Total

$

10,212

 

 

$

2,587

 

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Depreciation and Amortization

 

 

 

 

 

 

 

Photonics

$

3,244

 

 

$

1,544

 

Vision

 

2,437

 

 

 

3,100

 

Precision Motion

 

566

 

 

 

614

 

Unallocated Corporate and Shared Services

 

235

 

 

 

573

 

Total

$

6,482

 

 

$

5,831

 

 

 

 

22


 

I tem 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the Consolidated Financial Statements and Notes included in Item 1 of this Quarterly Report on Form 10-Q. The MD&A contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. These forward-looking statements include, but are not limited to, our belief that the Purchasing Managers Index (PMI) may provide an indication of the impact of general economic conditions on our sales into the advanced industrial end market; our strategy; anticipated financial performance; expected liquidity and capitalization; drivers of revenue growth; management’s plans and objectives for future operations, expenditures and product development and investments in research and development; business prospects; potential of future product releases; anticipated revenue performance; changes in accounting principles and changes in actual or assumed tax liabilities; and expectations regarding tax exposure. These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: the PMI not providing a good indication of the impact of general economic conditions on our sales into the advanced industrial end market in any particular period or at all; economic and political conditions and the effects of these conditions on our customers’ businesses and level of business activity; negative effect on global economic conditions, financial markets and our business as a result of the United Kingdom’s withdrawal from the European Union and the recent U.S. presidential election; our significant dependence upon our customers’ capital expenditures, which are subject to cyclical market fluctuations; our dependence upon our ability to respond to fluctuations in product demand; our ability to continually innovate and successfully commercialize our innovations; failure to introduce new products in a timely manner; customer order timing and other similar factors beyond our control; disruptions or breaches in security of our information technology systems; changes in interest rates, credit ratings or foreign currency exchange rates; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; our failure to comply with local import and export regulations in the jurisdictions in which we operate; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business or grow acquired businesses; our ability to attract and retain key personnel; our restructuring and realignment activities and disruptions to our operations as a result of consolidation of our operations; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components and other goods from our suppliers; production difficulties and product delivery delays or disruptions; our compliance, or our failure to comply, with various federal, state and foreign regulations; changes in governmental regulation of our business or products; effects of compliance with conflict minerals regulations; our compliance, or failure to comply, with environmental regulations; our failure to implement new information technology systems and software successfully; our failure to realize the full value of our intangible assets; our exposure to the credit risk of some of our customers and in weakened markets; our reliance on third party distribution channels; changes in tax laws, and fluctuations in our effective tax rates; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; volatility in the market price for our common shares; our ability to access cash and other assets of our subsidiaries; the influence of certain significant shareholders over our business; provisions of our articles of incorporation delaying or preventing a change in control; our significant existing indebtedness limiting our ability to engage in certain activities; and our failure to maintain appropriate internal controls in the future. Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 under the heading “Risk Factors.” In this Quarterly Report on Form 10-Q, the words “anticipates,” “believes,” “expects,” “intends,” “future,” “could,” “estimates,” “plans,” “would,” “should,” “potential,” “continues,” and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Management and the Company disclaim any obligation to publicly update or revise any such statement to reflect any change in its expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required under applicable law.

Accounting Period

The interim financial statements of Novanta Inc. and its subsidiaries (collectively referred to as the “Company”, “we”, “us”, “our”) are prepared for each quarterly period ending on the Friday closest to the end of the calendar quarter, with the exception of the fourth quarter which always ends on December 31.

23


 

Business Overview

We are a global supplier of core technology solutions that give healthcare and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in photonics, vision and precision motion with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is our team of innovative professionals who share a commitment to innovation and customer success.

Reportable Segments

We operate in three reportable segments: Photonics, Vision, and Precision Motion. The reportable segments and their principal activities consist of the following:

Photonics

The Photonics segment designs, manufactures and markets photonics-based solutions, including CO2 lasers, continuous wave and femtosecond lasers, optical light engines, and laser scanning and laser beam delivery products, to customers worldwide. The segment serves highly demanding photonics-based applications such as industrial material processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

Vision

Our Vision segment designs, manufactures and markets a range of medical grade technologies, including visualization solutions, imaging informatics products, optical data collection and machine vision technologies, radio frequency identification (“RFID”) technologies, thermal printers, light and color measurement instrumentation, and embedded touch screen solutions, to customers worldwide. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

Precision Motion

Our Precision Motion segment designs, manufactures and markets optical encoders, precision motor and motion control technology, air bearing spindles and precision machined components to customers worldwide. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

End Markets

We primarily operate in two end markets: the advanced industrial market and the medical market.

Advanced Industrial Market

As of March 31, 2017, the advanced industrial market accounted for approximately 60% of our revenue. Revenue from our products sold to the advanced industrial market is affected by a number of factors, including changing technology requirements and preferences of our customers, productivity or quality investments in a manufacturing environment, the financial condition of our customers, changes in regulatory requirements and laws, and general economic conditions. We believe that the Purchasing Managers Index (PMI) on manufacturing activities specific to different regions around the world may provide an indication of the impact of general economic conditions on our sales into the advanced industrial market.

Medical Market

As of March 31, 2017, the medical market accounted for approximately 40% of our revenue. Our revenue from products sold to the medical market is generally affected by hospital and other health care provider capital spending, changes in regulatory requirements and laws, aggregation of purchasing by healthcare networks, trends in surgical procedures, changes in technology requirements, changes in customers or patient preferences, and general demographic trends.

Strategy

24


 

Our strategy is to drive sustainable, profitable growth through short-term and long-term initiatives, including :

 

disciplined focus on our diversified business model of providing mission-critical functionality to long life-cycle OEM customer platforms in attractive medical and advanced industrial niche markets;

 

improving our business mix to increase medical sales as a percentage of total revenue by:

 

-

introducing new products aimed at attractive medical applications, such as minimally invasive and robotic surgery, ophthalmology, patient monitoring, drug delivery, clinical laboratory testing and life science equipment;

 

-

deepening our key account management relationships with and driving cross selling of our product offerings to leading medical equipment manufacturers; and

 

-

pursuing complementary medical technology acquisitions;

 

increasing our penetration of high growth advanced industrial applications, such as laser materials processing, robotics, automation and metrology, by working closely with OEM customers to launch application specific products that closely match the requirements of each application;

 

broadening our portfolio of enabling proprietary technologies and capabilities through increased investment in new product development, expanded sales and marketing channels to reach target customers, and investments in application development to further penetrate existing customers, while expanding the applicability of our solutions to new markets;

 

broadening our product and service offerings through the acquisition of innovative and complementary technologies and solutions in medical and advanced industrial technology applications, including increasing our recurring revenue streams such as services, spare parts and consumables;

 

improving our existing operations to expand profit margins and improve customer satisfaction by implementing lean manufacturing principles and strategic sourcing across our major production sites; and

 

attracting, retaining, and developing world-class talented and motivated employees.

Significant Events and Updates

Acquisition of Laser Quantum Limited

On January 10, 2017, the Company acquired an additional approximately 35% of the outstanding shares of Laser Quantum Limited (“Laser Quantum”), a Manchester, United Kingdom-based provider of solid state continuous wave lasers, femtosecond lasers, and optical light engines to OEMs in the medical market. Cash paid for the acquisition was £25.5 million ($31.1 million) and was financed with cash on hand and a $30.0 million draw-down on our revolving credit facility. In addition, the Company and the remaining equity holders entered into a call and put option agreement for the purchase and sale in 2020 of all remaining Laser Quantum shares held by the remaining equity holders, subject to certain conditions. The purchase price for the remaining shares will be based on a multiple of Laser Quantum’s EBITDA for the twelve months ending December 31, 2019, as defined in the call and put option agreement. As a result of this transaction, the Company’s ownership position in Laser Quantum increased from approximately 41% to approximately 76%. The financial results of Laser Quantum were previously accounted for under the equity method of accounting. As a result of the acquisition of the additional shares, the financial results of Laser Quantum have been consolidated in our consolidated financial statements since January 2017. In connection with the purchase price allocation under the business combination rules, we recognized a nontaxable gain of $26.4 million during the three months ended March 31, 2017, representing the excess fair value of our previously-held equity interest in Laser Quantum over its carrying value. Laser Quantum is included in our Photonics reportable segment.

Acquisition of ThingMagic

On January 10, 2017, the Company acquired ThingMagic, a Woburn, Massachusetts-based provider of ultra-high frequency (“UHF”) RFID modules and finished RFID readers to OEMs in the medical and advanced industrial markets, for a total purchase price of $19.2 million, subject to customary working capital adjustments. The acquisition was financed with cash on hand and a $12.0 million draw-down on our revolving credit facility. ThingMagic is included in our Vision reportable segment.

 

25


 

Results of Operations for the Three Months Ended March 31, 2017 Compared wit h the Three Months Ended April 1 , 20 16

The following table sets forth our unaudited results of operations as a percentage of revenue for the periods indicated:

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Revenue

 

100.0

%

 

 

100.0

%

Cost of revenue

 

57.7

 

 

 

59.2

 

Gross profit

 

42.3

 

 

 

40.8

 

Operating expenses:

 

 

 

 

 

 

 

Research and development and engineering

 

8.5

 

 

 

8.9

 

Selling, general and administrative

 

21.1

 

 

 

23.5

 

Amortization of purchased intangible assets

 

2.6

 

 

 

2.3

 

Restructuring, acquisition and divestiture related costs

 

0.7

 

 

 

3.2

 

Total operating expenses

 

32.9

 

 

 

37.9

 

Operating income from continuing operations

 

9.4

 

 

 

2.9

 

Interest income (expense), net

 

(1.2

)

 

 

(1.3

)

Foreign exchange transaction gains (losses), net

 

(0.0

)

 

 

0.1

 

Other income (expense), net

 

0.1

 

 

 

0.8

 

Gain on acquisition of business

 

24.2

 

 

 

 

Income from continuing operations before income taxes

 

32.5

 

 

 

2.5

 

Income tax provision

 

1.0

 

 

 

0.4

 

Income from continuing operations

 

31.5

 

 

 

2.1

 

Loss from discontinued operations, net of tax

 

 

 

 

 

Consolidated net income

 

31.5

 

 

 

2.1

 

Less: Net income attributable to noncontrolling interest

 

(0.0

)

 

 

 

Net income attributable to Novanta Inc.

 

31.4

%

 

 

2.1

%

 

Overview of Financial Results

Revenue for the three months ended March 31, 2017 was $109.0 million, an increase of $18.7 million, or 20.7%, versus the prior year. The net effect of our current year acquisitions and prior year decision to discontinue our radiology products resulted in an increase in revenue of $10.6 million, or 11.5%, Foreign currency exchange rates adversely impacted our revenue by $1.2 million, or 1.3%, during the three months ended March 31, 2017.

Operating income from continuing operations increased $7.6 million from $2.6 million for the three months ended April 1, 2016 to $10.2 million for the three months ended March 31, 2017. This increase was primarily attributable to an increase in gross profit of $9.2 million as a result of higher revenue and a decrease in restructuring, acquisition and divestiture related costs of $2.1 million, partially offset by an increase in other operating expenses of $3.7 million primarily due to current year and prior year acquisitions.

Diluted earnings per share (“Diluted EPS”) from continuing operations of $0.98 for the three months ended March 31, 2017 increased $0.93 from the prior year. This increase was primarily attributable to higher operating income from continuing operations, gain on acquisition of business, and a lower effective tax rate.

Revenue

The following table sets forth external revenue by reportable segment for the periods noted (dollars in thousands):

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

Increase

 

 

Percentage

 

 

2017

 

 

2016

 

 

(Decrease)

 

 

Change

 

Photonics

$

50,736

 

 

$

40,358

 

 

$

10,378

 

 

 

25.7

%

Vision

 

32,762

 

 

 

28,862

 

 

 

3,900

 

 

 

13.5

%

Precision Motion

 

25,476

 

 

 

21,096

 

 

 

4,380

 

 

 

20.8

%

Total

$

108,974

 

 

$

90,316

 

 

$

18,658

 

 

 

20.7

%

26


 

 

Photonics

Photonics segment revenue for the three months ended March 31, 2017 increased by $10.4 million, or 25.7%, versus the prior year primarily as a result of the Laser Quantum acquisition, which increased segment revenues by $7.2 million, and an increase in revenue of our laser beam delivery products and our CO2 lasers products of $3.2 million as a result of increased volumes in the advanced industrial and medical markets.

Vision

Vision segment revenue for the three months ended March 31, 2017 increased by $3.9 million, or 13.5%, versus the prior year. Revenue increased $4.7 million as a result of the acquisitions of Reach and ThingMagic, partially offset by a decline in revenue of $1.4 million attributable to our decision to discontinue our radiology products in January 2016.

Precision Motion

Precision Motion segment revenue for the three months ended March 31, 2017 increased by $4.4 million, or 20.8%, versus the prior year primarily due to an increase in revenue across all of our business lines as a result of increased demand in the advanced industrial and medical markets.

Gross Profit and Gross Profit Margin

The following table sets forth the gross profit and gross profit margin for each of our reportable segments for the periods noted (dollars in thousands):

 

  

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Gross profit:

 

 

 

 

 

 

 

Photonics

$

21,789

 

 

$

17,997

 

Vision

 

13,146

 

 

 

9,579

 

Precision Motion

 

11,518

 

 

 

9,668

 

Unallocated Corporate and Shared Services

 

(359

)

 

 

(352

)

Total

$

46,094

 

 

$

36,892

 

Gross profit margin:

 

 

 

 

 

 

 

Photonics

 

42.9

%

 

 

44.6

%

Vision

 

40.1

%

 

 

33.2

%

Precision Motion

 

45.2

%

 

 

45.8

%

 

 

 

 

 

 

 

 

Total

 

42.3

%

 

 

40.8

%

 

Gross profit and gross profit margin can be influenced by a number of factors, including product mix, pricing, volume, manufacturing efficiencies and utilization, costs for raw materials and outsourced manufacturing, headcount, inventory obsolescence and warranty expenses.

Photonics

Photonics segment gross profit for the three months ended March 31, 2017 increased $3.8 million, or 21.1%, versus the prior year, primarily due to an increase in revenue as a result of the Laser Quantum acquisition, which increased gross profit by $2.7 million. Photonics segment gross profit margin was 42.9% for the three months ended March 31, 2017, versus a gross profit margin of 44.6% for the prior year. The decrease in gross profit margin was primarily attributable to an increase in amortization of inventory fair value adjustments and amortization of developed technology of $1.3 million, which resulted in a 2.6 percentage point decrease in gross profit margin.

Vision

Vision segment gross profit for the three months ended March 31, 2017 increased $3.6 million, or 37.2%, versus the prior year. The increase was primarily attributable to an increase in revenue from the Reach and ThingMagic acquisitions and the discontinuation

27


 

of our radiology products in January 2016 . Vision s egment gross profit margin was 40 . 1 % for the three months ended March 31 , 201 7 , versus a gross profit margin of 33 .2% for the prior year. The in crease in gross profit margin was primarily attributable to a $1.6 million charge in the prior year related to the discontinuation of our radiology products , which had a 5.4 percentage point unfavorable impact on gross profit margin for the three months ended April 1, 2016 .

Precision Motion

Precision Motion segment gross profit for the three months ended March 31, 2017 increased $1.8 million, or 19.1%, versus the prior year. The increase was primarily attributable to an increase in revenue. Precision Motion segment gross profit margin was 45.2% for the three months ended March 31, 2017, versus a gross profit margin of 45.8% for the prior year. The decrease in gross profit margin was attributable to changes in product mix.

Operating Expenses

The following table sets forth operating expenses for the periods noted (in thousands):

 

  

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Research and development and engineering

$

9,215

 

 

$

8,052

 

Selling, general and administrative

 

23,001

 

 

 

21,187

 

Amortization of purchased intangible assets

 

2,849

 

 

 

2,108

 

Restructuring, acquisition and divestiture related costs

 

817

 

 

 

2,958

 

Total

$

35,882

 

 

$

34,305

 

 

Research and Development and Engineering Expenses

Research and development and engineering (“R&D”) expenses are primarily comprised of employee compensation related expenses and cost of materials for R&D projects. R&D expenses were $9.2 million, or 8.5% of revenue, during the three months ended March 31, 2017, versus $8.1 million, or 8.9% of revenue, during the prior year. R&D expenses increased in terms of total dollars primarily due to increased R&D expenses from current and prior year acquisitions.

Selling, General and Administrative Expenses

Selling, general and administrative (“SG&A”) expenses include costs for sales and marketing, sales administration, finance, human resources, legal, information systems, and executive management functions. SG&A expenses were $23.0 million, or 21.1% of revenue, during the three months ended March 31, 2017, versus $21.2 million, or 23.5% of revenue, during the prior year. SG&A expenses increased in terms of total dollars primarily due to current and prior year acquisitions and investments in sales and marketing resources.

Amortization of Purchased Intangible Assets

Amortization of purchased intangible assets, excluding the amortization of developed technologies included in cost of revenue, was $2.8 million, or 2.6% of revenue, during the three months ended March 31, 2017, versus $2.1 million, or 2.3% of revenue, during the prior year. The increase, in terms of total dollars and as a percentage of revenue, was related to the increase in amortization of acquired intangible assets from current and prior year acquisitions.

Restructuring, Acquisition and Divestiture Related Costs

We recorded restructuring, acquisition and divestiture related costs of $0.8 million during the three months ended March 31, 2017, versus $3.0 million during the prior year. The decrease in restructuring, acquisition and divestiture related costs versus the prior year was due to a decrease in restructuring related charges of $2.7 million as a result of the 2016 restructuring program which was substantially completed in the prior year, partially offset by an increase in acquisition related charges of $0.5 million related to professional services fees for acquisitions.

28


 

Operating Income from Continuing Operations by Segment

The following table sets forth operating income from continuing operations by segment for the periods noted (in thousands):

 

  

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Operating Income (Loss) from Continuing Operations:

 

 

 

 

 

 

 

Photonics

$

8,080

 

 

$

6,856

 

Vision

 

1,525

 

 

 

(3,771

)

Precision Motion

 

7,164

 

 

 

5,235

 

Unallocated Corporate and Shared Services

 

(6,557

)

 

 

(5,733

)

Total

$

10,212

 

 

$

2,587

 

 

Photonics

Photonics operating income from continuing operations for the three months ended March 31, 2017 increased by $1.2 million, or 17.9%, versus the prior year. The increase in operating income from continuing operations was primarily due to an increase in revenues from our CO2 lasers and laser beam delivery products in addition to the operating income from the Laser Quantum acquisition. Photonics operating income from continuing operations for the three months ended March 31, 2017 was negatively affected by a $2.1 million increase in amortization of inventory fair value adjustments and amortization of intangible assets.

Vision

Vision operating income from continuing operations for the three months ended March 31, 2017 was $1.5 million, which increased $5.3 million from an operating loss of $3.8 million in the prior year. The increase was attributable to an increase in gross profit of $3.6 million and a decrease in restructuring charges of $1.7 million primarily related to our 2016 restructuring program, which was substantially completed in the second quarter of 2016.

Precision Motion

Precision Motion operating income from continuing operations for the three months ended March 31, 2017 increased by $1.9 million, or 36.8%, versus the prior year. The increase was primarily due to an increase in gross profit of $1.8 million.  

Unallocated Corporate and Shared Services

Unallocated corporate and shared services costs primarily represent costs of corporate and shared services functions that are not allocated to the operating segments, including certain restructuring and most acquisition related costs. These costs for the three months ended March 31, 2017 increased by $0.8 million, or 14.4%, versus the prior year primarily due to an increase in SG&A expenses as a result of higher variable compensation associated with the Company’s financial performance.

Other Income and Expense Items

The following table sets forth other income and expense items for the periods noted (in thousands):

 

 

Three Months Ended

 

 

March 31,

 

 

April 1,

 

 

2017

 

 

2016

 

Interest income (expense), net

$

(1,328

)

 

$

(1,185

)

Foreign exchange transaction gains (losses), net

 

(1

)

 

 

83

 

Other income (expense), net

 

96

 

 

 

743

 

Gain on acquisition of business

 

26,409

 

 

 

 

 

 

29


 

Interest Income (Expense), Net

Net interest expense was $1.3 million for the three months ended March 31, 2017, versus $1.2 million in the prior year. The increase in net interest expense from the prior year was primarily due to an increase in average debt levels.  The weighted average interest rate on our senior credit facilities was 3.66% during the three months ended March 31, 2017, versus 3.42% for the three months ended April 1, 2016.

Foreign Exchange Transaction Gains (Losses), Net

Foreign exchange transaction gains (losses), net, were nominal for the three months ended March 31, 2017, versus less than $0.1 million net gains for the prior year.

Other Income (Expense), Net

Other income was $0.1 million for the three months ended March 31, 2017, versus $0.7 million in the prior year. The decrease in other income was primarily due to earnings from our equity-method investment in Laser Quantum having been reported in other income (expense) in the prior year. In January 2017, the Company acquired an additional approximately 35% of the outstanding shares of Laser Quantum. As a result of this acquisition, earnings from Laser Quantum are consolidated in the Company’s consolidated financial statements for the three months ended March 31, 2017.

Gain on Acquisition of Business

The gain on acquisition of business during the three months ended March 31, 2017 was related to a nontaxable gain of $26.4 million recognized as a result of the Laser Quantum acquisition in January 2017.

Income Taxes

The effective tax rate for the three months ended March 31, 2017 was 3.1%, versus 14.5% for the prior year. The Company’s effective tax rate on income from continuing operations of 3.1% for the three months ended March 31, 2017 differs from the Canadian statutory rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, the impact associated with establishing control over Laser Quantum upon the acquisition of an additional 35% of Laser Quantum’s outstanding shares, losses in jurisdictions with a full valuation allowance, and other discrete items for the period. The Company reported a nontaxable gain of $26.4 million on its previously-held Laser Quantum equity interest and wrote off $1.4 million of Laser Quantum related deferred tax liability, which had a combined 24.5% favorable impact on our effective tax rate for the three months ended March 31, 2017.

The Company’s effective tax rate on income from continuing operations of 14.5% for the three months ended April 1, 2016 differed from the Canadian statutory rate primarily due to the mix of income earned in jurisdictions with varying tax rates, losses in jurisdictions with a full valuation allowance, the Laser Quantum dividend distribution and the impact of other discrete items for the period. The Company received a tax free cash dividend of $2.3 million from Laser Quantum, which had an 18.9% favorable impact on our effective tax rate for the three months ended April 1, 2016.

 

 

Liquidity and Capital Resources

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing, and financing activities. Our primary ongoing cash requirements are funding operations, capital expenditures, investments in businesses, and repayment of our debt and related interest payments. Our primary sources of liquidity are cash flows from operations and borrowings under our revolving credit facility. We believe our future operating cash flows will be sufficient to meet our future operating and capital expenditure cash needs for the foreseeable future, including at least the next 12 months. The availability of borrowings under our revolving credit facility provides an additional potential source of liquidity for acquisitions. In addition, we may seek to raise additional capital, which could be in the form of bonds, convertible debt or equity, to fund major business development activities or other future investing cash requirements, subject to approval by the lenders in the Second Amended and Restated Credit Agreement.

Significant factors affecting the management of our ongoing cash requirements are the adequacy of available bank lines of credit and our ability to attract long term capital with satisfactory terms. The sources of our liquidity are subject to all of the risks of our business and could be adversely affected by, among other factors, a decrease in demand for our products, our ability to integrate current and future acquisitions, deterioration in certain financial ratios, and market changes in general. See “Risks Relating to Our Common Shares and Our Capital Structure” included in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

30


 

Our ability to make payments on our indebtedness and to fund our operations may be dependent upon the earnings and the distribution of funds from our subsidiaries. Local laws and regulations and/or the terms of our indebtedness restrict certain of our subsidiaries from paying dividends and transferring assets to us. We cannot assure you that appli cable laws and regulations and/or the terms of our indebtedness will permit our subsidiaries to provide us with sufficient dividends, distributions or loans when necessary .

In October 2013, the Company’s Board of Directors authorized a share repurchase plan under which the Company may repurchase outstanding shares of the Company’s common stock up to an aggregate amount of $10.0 million. The shares may be repurchased from time to time, at the Company’s discretion, based on ongoing assessment of the capital needs of the business, the market price of the Company’s common stock, and general market conditions. Shares may also be repurchased through an accelerated stock purchase agreement, on the open market or in privately negotiated transactions in accordance with applicable federal securities laws. Repurchases may be made under certain SEC regulations, which would permit common stock to be purchased when the Company would otherwise be prohibited from doing so under insider trading laws. The share repurchase plan does not obligate the Company to acquire any particular amount of common stock. No time limit was set for the completion of the share repurchase program, and the program may be suspended or discontinued at any time. The Company expects to fund share repurchases through cash on hand and future cash flows from operations. As of December 31, 2016, the Company had repurchased 282 thousand shares for an aggregate purchase price of $3.8 million at an average price of $13.43 per share. During the three months ended March 31, 2017, the Company repurchased 14 thousand shares in the open market for an aggregate purchase price of $0.4 million at an average price of $26.41 per share.

As of March 31, 2017, $52.3 million of our $80.0 million cash and cash equivalents was held by our subsidiaries outside of Canada and the United States. Generally, our intent is to use cash held in these foreign subsidiaries to fund our local operations or acquisitions by those local subsidiaries. However, in certain instances, we have identified excess cash for which we may repatriate and we have established deferred tax liabilities for the expected tax cost. Additionally, we may use intercompany loans to address short-term cash flow needs for various subsidiaries.

Second Amended and Restated Credit Agreement

In May 2016, we entered into the second amended and restated senior secured credit agreement (the “Second Amended and Restated Credit Agreement”), consisting of a $75.0 million, 5-year term loan facility and a $225.0 million, 5-year revolving credit facility (collectively, the “Senior Credit Facilities”). The Senior Credit Facilities mature in May 2021. As of March 31, 2017, we had term loans of $69.4 million and revolving loans of $52.0 million outstanding under the Second Amended and Restated Credit Agreement.

The Second Amended and Restated Credit Agreement contains various covenants that we believe are usual and customary for this type of agreement, including a maximum allowed leverage ratio, and a minimum required fixed charge coverage ratio (as defined in the Second Amended and Restated Credit Agreement). The following table summarizes these financial covenant requirements and our compliance as of March 31, 2017:

 

 

Requirement

 

 

Actual

 

Maximum consolidated leverage ratio

 

3.00

 

 

 

1.54

 

Minimum consolidated fixed charge coverage ratio

 

1.50

 

 

 

5.10

 

 

Cash Flows for the Three Months Ended March 31, 2017 and April 1, 2016

The following table summarizes our cash flows from continuing operations, cash and cash equivalent balances and unused and available funds under our revolving credit facility for the periods indicated (in thousands):

 

 

Three Months Ended

 

 

March 31,

2017

 

 

April 1,

2016

 

Net cash provided by operating activities of continuing operations

$

12,760

 

 

$

8,298

 

Net cash provided by (used in) investing activities of continuing operations

$

(36,656

)

 

$

1,670

 

Net cash provided by (used in) financing activities of continuing operations

$

35,473

 

 

$

(3,449

)

31


 

 

 

March 31,

2017

 

 

December 31,

2016

 

Cash and cash equivalents

$

80,014

 

 

$

68,108

 

Unused and available funds under revolving credit facility

$

173,000

 

 

$

215,000

 

 

Operating Cash Flows

Cash provided by operating activities of continuing operations was $12.8 million for the three months ended March 31, 2017, versus $8.3 million for the prior year. Cash provided by operating activities of continuing operations for the three months ended March 31, 2017 increased from the prior year primarily due to the increase in income from continuing operations.

Cash provided by operating activities of continuing operations was positively impacted by an increase in our payables outstanding. Cash provided by operating activities of continuing operations was negatively impacted by an increase in our days sales outstanding which increased from 59 days at December 31, 2016 to 60 days at March 31, 2017 and by an increase in inventories, excluding inventories from the Laser Quantum and ThingMagic acquisitions, as our inventory turnover ratio decreased from 3.7 at December 31, 2016 to 3.6 at March 31, 2017.

Cash provided by operating activities of continuing operations for the three months ended April 1, 2016 was positively impacted by an increase in our days payables outstanding which increased from 41 days at December 31, 2015 to 46 days at April 1, 2016. Cash provided by operating activities of continuing operations was negatively impacted by an increase in our days sales outstanding which increased from 57 days at December 31, 2015 to 60 days at April 1, 2016 and by an increase in inventory as our inventory turnover ratio decreased from 3.6 at December 31, 2015 to 3.4 at April 1, 2016. The Company’s days sales outstanding was impacted by the timing of sales occurring later in the first quarter of 2016 compared to the prior year.

Investing Cash Flows

Cash used in investing activities of continuing operations was $36.7 million for the three months ended March 31, 2017, primarily driven by our acquisitions of ThingMagic and Laser Quantum. In connection with these acquisitions, we paid $50.2 million in cash considerations, which is reported as $34.9 million cash outflows (net of cash acquired of $15.3 million) from investing activities for the three months ended March 31, 2017. We also paid $1.8 million for capital expenditures during the three months ended March 31, 2017.

Cash provided by investing activities of continuing operations was $1.7 million for the three months ended April 1, 2016. This was primarily driven by the $3.6 million net cash consideration received from the sale of our Orlando, Florida facility and $0.4 million cash received upon finalization of the Lincoln Laser acquisition working capital adjustments, partially offset by $2.3 million in capital expenditures.

Cash provided by investing activities of discontinued operations for the three months ended April 1, 2016 was related to $1.5 million cash proceeds released from escrow for our Scientific Lasers divestiture.

Financing Cash Flows

Cash provided by financing activities of continuing operations was $35.5 million during the three months ended March 31, 2017, primarily due to $42.0 million of borrowings under our revolving credit facility used to pay a portion of the cash considerations paid for the ThingMagic and Laser Quantum acquisitions, partially offset by $1.9 million of contractual term loan payments, $2.4 million of contingent consideration payments, $1.7 million of payroll tax payments on stock-based compensation awards, $0.4 million of repurchase of the Company’s common shares and $0.2 million of capital lease payments.

Cash used in financing activities of continuing operations was $3.4 million during the three months ended April 1, 2016, consisting of $1.9 million of contractual term loan payments, $1.3 million of payroll tax payments on stock-based compensation awards and $0.3 million of capital lease payments.

 

 

Off-Balance Sheet Arrangements, Contractual Obligations

Contractual Obligations

Our contractual obligations primarily consist of the principal and interest associated with our debt, operating and capital leases, purchase commitments and pension obligations. Such contractual obligations are described in our Management’s Discussion and

32


 

Analysis of Financial Condition and Results of Operations and in the Notes to Consolidated Financial Statements, each included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Excluding the $42.0 milli on borrowings under our revolving credit facility to fund the Laser Quantum and ThingMagic acquisitions, through March 31, 2017 , we have not entered into any material new or modified contractual obligations since December 31, 201 6 . Borrowings under our rev olving credit facility are due in May 2021, the maturity date of our Senior Credit Facilities, and may be repaid at any time before then without prepayment penalties.

Off-Balance Sheet Arrangements

Through March 31, 2017, we have not entered into any other off-balance sheet arrangements or material transactions with any unconsolidated entities or other persons.

Critical Accounting Policies and Estimates

The critical accounting policies that we believe impact significant judgments and estimates used in the preparation of our consolidated financial statements presented in this periodic report on Form 10-Q are described in our Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to Consolidated Financial Statements, each included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. There have been no material changes to our critical accounting policies through March 31, 2017 from those discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

Recent Accounting Pronouncements

See Note 1 to Consolidated Financial Statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our primary market risk exposures are foreign currency exchange rate fluctuations and interest rate sensitivity. During the three months ended March 31, 2017, there have been no material changes to the information included under Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities and Exchange Act of 1934 (the “Exchange Act”), our management carried out an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of March 31, 2017, the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2017.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting that occurred during the fiscal quarter ended March 31, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

33


 

P ART II—OTHER INFORMATION

 

Item 1. Legal Proceedings

The Company is subject to various legal proceedings and claims that arise in the ordinary course of business. The Company does not believe that the outcome of these claims will have a material adverse effect upon its financial condition or results of operations but there can be no assurance that any such claims, or any similar claims, would not have a material adverse effect upon its financial condition or results of operations.

 

Item 1A. Risk Factors

The Company’s risk factors are described in Part I, Item 1A, “Risk Factors”, of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016. There have been no material changes in the risks affecting the Company since the filing of such Annual Report on Form 10-K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table sets forth certain information with respect to repurchases of the Company’s common shares during the three months ended March 31, 2017.

 

ISSUER PURCHASES OF EQUITY SECURITIES

 

Period

 

Total Number of Shares Purchased

 

 

Average Price Paid per Share

 

 

Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)(2)

 

 

Approximate Dollar Value that May Yet Be Purchased Under the Plans or Programs (1)

 

January 1 - January 27, 2017

 

 

 

 

$

 

 

 

 

 

$

6,213,509

 

January 28 - February 24, 2017

 

 

14,000

 

 

$

26.41

 

 

 

14,000

 

 

$

5,843,800

 

February 25 - March 31, 2017

 

 

 

 

$

 

 

 

 

 

$

5,843,800

 

Total

 

 

14,000

 

 

$

26.41

 

 

 

14,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) In October 2013, the Company's Board of Directors authorized a share repurchase plan for the repurchase of up to an aggregate of $10.0 million of the Company's common shares. The share repurchase plan was announced in the quarterly report for the period ended September 27, 2013 filed on November 5, 2013. The shares may be repurchased from time to time, at the Company's discretion, based on ongoing assessment of the capital needs of the business, the market price of the Company's common shares, and general market conditions. No time limit was set for the completion of the share repurchase program, and the program may be suspended or discontinued at any time.

 

(2) The Company has repurchased 295,893 shares of its common shares pursuant to the share repurchase program since its adoption.

 

 

Item 3. Defaults Upon Senior Securities

None.

 

Item 4. Mine Safety Disclosures

None.

 

Item 5. Other Information

None.

 

34


 

I tem 6. Exhibits

List of Exhibits

See the Company’s SEC filings on Edgar at: http://www.sec.gov/ for all Exhibits.

 

 

  

 

  

Incorporated by Reference

Exhibit

Number

  

Exhibit Description

  

Form

  

File No.

  

Exhibit

  

Filing

Date

  

Filed/

Furnished
Herewith

 

 

 

 

 

 

 

3.1

  

Certificate and Articles of Continuance of the Registrant, dated March 22, 1999.

  

S-3

 

333-202597

 

3.1

 

03/09/15

 

 

 

 

 

 

 

 

 

3.2

  

By-Laws of the Registrant, as amended

  

10-Q

 

000-25705

 

3.2

 

04/13/10

 

 

 

 

 

 

 

 

 

3.3

  

Articles of Reorganization of the Registrant, dated July 23, 2010.

  

8-K

 

000-25705

 

3.1

 

07/23/10

 

 

 

 

 

 

 

 

 

3.4

  

Articles of Amendment of the Registrant, dated December 29, 2010.

  

S-3

 

333-202597

 

3.2

 

03/09/15

 

 

 

 

 

 

 

 

 

3.5

 

Articles of Amendment of the Registrant, dated May 11, 2016.

 

8-K

 

001-35083

 

10.1

 

05/12/16

 

 

 

 

 

 

 

 

 

10.1

 

Form of Restricted Stock Unit Award Agreement and Grant Notice.

 

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

10.2

 

Form of Performance Stock Unit Award Agreement and Grant Notice.

 

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

10.3

 

Amended and Restated Employment Agreement, dated April 21, 2017 between the Registrant and Matthijs Glastra.

 

8-K

 

001-35083

 

10.1

 

04/21/17

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.4

 

Amended and Restated Employment Agreement, dated April 21, 2017 between the Registrant and Robert Buckley.

 

8-K

 

001-35083

 

10.2

 

04/21/17

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.5

 

Employment Agreement, dated April 21, 2017 between the Registrant and Brian Young.

 

8-K

 

001-35083

 

10.3

 

04/21/17

 

 

 

 

 

 

 

 

 

31.1

  

Chief Executive Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

31.2

  

Chief Financial Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

32.1

  

Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

  

 

 

 

 

 

 

 

 

**

 

 

 

 

 

 

 

32.2

  

Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

  

 

 

 

 

 

 

 

 

**

 

 

 

 

 

 

 

101.INS

  

XBRL Instance Document.

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

101.SCH

  

XBRL Schema Document

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

101.CAL

  

XBRL Calculation Linkbase Document.

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

101.DEF

  

XBRL Definition Linkbase Document.

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

101.LAB

  

XBRL Labels Linkbase Document.

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

101.PRE

  

XBRL Presentation Linkbase Document.

  

 

 

 

 

 

 

 

 

*

 

* Filed herewith

** Furnished herewith

35


 

Attached as Exhibit 101 to this report are the following formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets at March 31, 2017 and December 31, 201 6 , (ii) Consolidated Statements of Operations for the three months ended March 31, 2017 and April 1, 2016 , (iii) Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2017 and April 1, 2016 , (iv) Consolidated Statements of Cash Flows for the three months ended March 31, 2017 and April 1, 2016 , and (v) Notes to Consolidated Financial Statements.

36


 

S IGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Novanta Inc. (Registrant)

 

Name

  

Title

 

Date

 

 

 

 

 

/s/ Matthijs Glastra

  

Director, Chief Executive Officer

 

May 8, 2017

Matthijs Glastra

  

 

 

 

 

 

 

/s/ Robert J. Buckley

  

Chief Financial Officer

 

May 8, 2017

Robert J. Buckley

  

 

 

 

 

37


 

E XHIBIT INDEX

 

 

  

 

  

Incorporated by Reference

Exhibit

Number

  

Exhibit Description

  

Form

  

File No.

  

Exhibit

  

Filing

Date

  

Filed/

Furnished
Herewith

 

 

 

 

 

 

 

3.1

  

Certificate and Articles of Continuance of the Registrant, dated March 22, 1999.

  

S-3

 

333-202597

 

3.1

 

03/09/15

 

 

 

 

 

 

 

 

 

3.2

  

By-Laws of the Registrant, as amended

  

10-Q

 

000-25705

 

3.2

 

04/13/10

 

 

 

 

 

 

 

 

 

3.3

  

Articles of Reorganization of the Registrant, dated July 23, 2010.

  

8-K

 

000-25705

 

3.1

 

07/23/10

 

 

 

 

 

 

 

 

 

3.4

  

Articles of Amendment of the Registrant, dated December 29, 2010.

  

S-3

 

333-202597

 

3.2

 

03/09/15

 

 

 

 

 

 

 

 

 

3.5

 

Articles of Amendment of the Registrant, dated May 11, 2016.

 

8-K

 

001-35083

 

10.1

 

05/12/16

 

 

 

 

 

 

 

 

 

10.1

 

Form of Restricted Stock Unit Award Agreement and Grant Notice.

 

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

10.2

 

Form of Performance Stock Unit Award Agreement and Grant Notice.

 

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

10.3

 

Amended and Restated Employment Agreement, dated April 21, 2017 between the Registrant and Matthijs Glastra.

 

8-K

 

001-35083

 

10.1

 

04/21/17

 

 

 

 

 

 

 

 

 

10.4

 

Amended and Restated Employment Agreement, dated April 21, 2017 between the Registrant and Robert Buckley.

 

8-K

 

001-35083

 

10.2

 

04/21/17

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.5

 

Employment Agreement, dated April 21, 2017 between the Registrant and Brian Young.

 

8-K

 

001-35083

 

10.3

 

04/21/17

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31.1

  

Chief Executive Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

31.2

  

Chief Financial Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

32.1

  

Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

  

 

 

 

 

 

 

 

 

**

 

 

 

 

 

 

 

32.2

  

Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

  

 

 

 

 

 

 

 

 

**

 

 

 

 

 

 

 

101.INS

  

XBRL Instance Document.

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

101.SCH

  

XBRL Schema Document

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

101.CAL

  

XBRL Calculation Linkbase Document.

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

101.DEF

  

XBRL Definition Linkbase Document.

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

101.LAB

  

XBRL Labels Linkbase Document.

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

101.PRE

  

XBRL Presentation Linkbase Document.

  

 

 

 

 

 

 

 

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

* Filed herewith

** Furnished herewith

38


 

Attached as Exhibit 101 to this report are the following formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets at March 31, 2017 and December 31, 20 16 , (ii) Consolidated Statements of Operations for the three months ended March 31, 2017 and April 1 , 20 16 , (iii) Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2017 and April 1, 2016 , (iv) Consolidated Statemen ts of Cash Flows for the three months ended March 31, 2017 and April 1, 2016 , and (v) Notes to Consolidated Financial Statements.

 

 

39

 

Exhibit 10.1

Novanta INC.
2010 INCENTIVE AWARD PLAN

RESTRICTED STOCK UNIT AWARD GRANT NOTICE

Novanta Inc. (f/k/a GSI Group Inc.), a company organized under the laws of the Province of New Brunswick, Canada (together with any successor thereto, the “ Company ”), pursuant to the Novanta Inc. 2010 Incentive Award Plan, as amended from time to time (the “ Plan ”), hereby grants to the holder listed below (“ Participant ”), an award of restricted stock units (“ Restricted Stock Units ”).  Each Restricted Stock Unit represents the right to receive one share of Common Stock (as defined in the Plan) upon vesting of such Restricted Stock Unit.  This award of Restricted Stock Units is subject to all of the terms and conditions set forth herein and in the Restricted Stock Unit Award Agreement attached hereto as Exhibit A (the “ Restricted Stock Unit Award Agreement ”) and the Plan, each of which are incorporated herein by reference.  

Participant:

 

Total Number of Restricted Stock Units:

 

By his or her signature and the Company’s signature below, Participant agrees to be bound by the terms and conditions of the Plan, the Restricted Stock Unit Award Agreement, this Grant Notice and that certain Employee Patent and Proprietary Information Utilization, Non-Competition and Non-Solicitation Agreement in the form attached hereto as Exhibit B (the “ Employee Agreement ”).  Participant has reviewed the Restricted Stock Unit Award Agreement, the Plan, this Grant Notice and the Employee Agreement in their entirety and fully understands all provisions of this Grant Notice, the Restricted Stock Unit Award Agreement, the Plan and the Employee Agreement.  Participant shall sign and return a written copy of the Employee Agreement to the Company as soon as practicable following.  

 

Novanta Inc.: Holder:

PARTICIPANT:

By:

 

By:

 

Print Name:

 

Name:  

 

Title:

 

  

 

Address:

 

Address:

 

 

 

 

 

 

 


 

EXHIBIT A

TO RESTRICTED STOCK UNIT AWARD GRANT NOTICE

NOVANTA INC. RESTRICTED STOCK UNIT AWARD AGREEMENT

Pursuant to the Restricted Stock Unit Award Grant Notice (the “ Grant Notice ”) to which this Restricted Stock Unit Award Agreement (this “ Agreement ”) is attached, Novanta Inc. (f/k/a GSI Group Inc.), a company organized under the laws of the Province of New Brunswick, Canada (the “ Company ”), has granted to Participant an award of restricted stock units (“ Restricted Stock Units or RSUs ”) under the Novanta Inc. 2010 Incentive Award Plan, as amended from time to time (the “ Plan ”).  

ARTICLE 1.
GENERAL

1.1 Defined Terms .  Capitalized terms not specifically defined herein shall have the meanings specified in the Grant Notice or the Plan.  As used herein, the term “stock unit” shall mean a non-voting unit of measurement which is deemed for bookkeeping purposes to be equivalent to one outstanding share of Common Stock (subject to adjustment as provided in Article 14 of the Plan) solely for purposes of the Plan and this Agreement.  The Restricted Stock Units shall be used solely as a device for the determination of the payment to eventually be made to Participant if such Restricted Stock Units vest pursuant to Section 2.3 hereof.  The Restricted Stock Units shall not be treated as property or as a trust fund of any kind.

1.2 Incorporation of Terms of Plan .  The RSUs are subject to the terms and conditions of the Plan which are incorporated herein by reference.  In the event of any conflict between the provisions of this Agreement and the Plan, the terms of the Plan shall control.

ARTICLE 2.
GRANT OF RESTRICTED STOCK UNITS

2.1 Grant of RSUs .  In consideration of Participant’s past and/or continued employment with or service to the Company or a Subsidiary and for other good and valuable consideration, effective as of (the “ Grant Date ”), the Company grants to Participant an award of RSUs as set forth in the Grant Notice, upon the terms and conditions set forth in the Plan and this Agreement, subject to adjustments as provided in Article 14 of the Plan.  

2.2 Company’s Obligation to Pay .  Each RSU has a value equal to the Fair Market Value of a share of Common Stock on the date it becomes vested.  Unless and until the RSUs will have vested in the manner set forth in Article 2 hereof, Participant will have no right to payment of any such RSUs.  Prior to actual payment of any vested RSUs, such RSUs will represent an unsecured obligation of the Company, payable (if at all) only from the general assets of the Company.  

2.3 Vesting Schedule .  

(a) Subject to Sections 2.3(b) and 2.5 hereof, the RSUs awarded by the Grant Notice will, subject to Participant’s continued employment or services through the applicable vesting dates, vest and become nonforfeitable with respect to the applicable portion thereof according to the following vesting schedule:  

A-1

 


 

(i) Other than with respect to the final installment, the number of RSUs that shall vest and become nonforfeitable on each applicable vesting date shall be rounded down to the next whole number.  Except as set forth in Section 2.3(b), unless otherwise determined by the Administrator, partial employment or service, even if substantial, during any vesting period will not entitle Participant to any proportionate vesting or avoid or mitigate a termination of rights and benefits upon or following a Termination of Service as provided in Section 2.5 hereof or under the Plan.

(b) Notwithstanding Section 2.3(a) hereof, the RSUs will become fully vested and nonforfeitable with respect to all shares of Common Stock covered thereby upon the date of Participant’s Termination of Service by the Company without Cause if such Termination of Service occurs on or within twelve (12) months following a Change in Control.  For purposes of this Agreement, “ Cause ” shall have the meaning of “Cause” (or similar term) set forth in Participant’s written employment or similar agreement or, if no such written employment or similar agreement (or no definition of “Cause” or similar term therein), shall mean (i) Participant’s willful failure to substantially perform his or her duties; (ii) Participant’s willful failure to carry out, or comply with, in any material respect any lawful and reasonable directive of the Board (or his or her supervisor); (iii) Participant’s commission at any time of any act or omission that results in, or may reasonably be expected to result in, a conviction, plea of no contest, plea of nolo contendere , or imposition of unadjudicated probation for any felony or crime involving moral turpitude; or (iv) Participant’s unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing Participant’s duties and responsibilities for the Company or any of its Subsidiaries.

2.4 Consideration to the Company .  As a condition precedent to the grant of the award of RSUs by the Company, Participant shall have executed and delivered to the Company an Employee Patent and Proprietary Information Utilization, Non-Competition and Non-Solicitation Agreement (or similar agreement) in the Company’s then-applicable form.  In further consideration of the grant of the award of RSUs by the Company, Participant agrees to render faithful and efficient services to the Company or any Subsidiary.  Nothing in the Plan or this Agreement shall confer upon Participant any right to continue in the employ or service of the Company or any Subsidiary or shall interfere with or restrict in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.

2.5 Forfeiture, Termination and Cancellation upon Termination of Service .  Notwithstanding any contrary provision of this Agreement, except as otherwise set forth in Section 2.3(b), upon Participant’s Termination of Service for any or no reason, all then unvested RSUs subject to this Agreement will thereupon be automatically forfeited, terminated and cancelled as of the applicable termination date without payment of any consideration by the Company, and Participant, or Participant’s beneficiary or personal representative, as the case may be, shall have no further rights hereunder.

2.6 Payment upon Vesting .  

(a) As soon as administratively practicable following the vesting of any Restricted Stock Units pursuant to Section 2.3 hereof, but in no event later than sixty (60) days after such vesting date (for the avoidance of doubt, this deadline is intended to comply with the “short-term deferral” exemption from Section 409A of the Code), the Company shall deliver to Participant (or any transferee permitted under Section 3.2 hereof) a number of shares of Common Stock (either by delivering one or more certificates for such shares or by entering such shares in book entry form, as determined by the

A-2

 


 

Company in its sole discretion) equal to the number of Restricted Stock Units subject to this award that vest on the applicable vesting date, unless such Restricted Stock Units terminate prior to the given vesting date pursuant to Section 2.5 hereof.  Notwithstanding the foregoing, in the event shares of Common Stock cannot be issued pursuant to Section 2.7(a) , (b) or (c) hereof, then the shares of Common Stock shall be issued pursuant to the preceding sentence as soon as administratively practicable after the Administrator determines that shares of Common Stock can again be issued in accordance with Sections 2.7(a) , (b) and (c) hereof.

(b) Notwithstanding anything to the contrary in this Agreement, the Company shall be entitled to require payment by Participant of any sums required by applicable law to be withheld with respect to the grant of RSUs or the issuance of shares of Common Stock.  Such payment shall be made by deduction from other compensation payable to Participant or in the following other form of consideration:

(i) Cash or check;

(ii) With the consent of the Administrator, surrender of shares of Common Stock (including, without limitation, shares of Common Stock otherwise issuable under the RSUs) held for such period of time as may be required by the Administrator in order to avoid adverse accounting consequences and having a Fair Market Value on the date of delivery not greater than the aggregate amount required to be withheld based on the maximum statutory withholding rates in Participant’s applicable jurisdiction for federal, state, local and foreign income tax and payroll tax purposes; or

(iii) Other property acceptable to the Administrator (including, without limitation, through the delivery of a notice that Participant has placed a market sell order with a broker with respect to shares of Common Stock then issuable under the RSUs, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of its withholding obligations; provided that payment of such proceeds is then made to the Company upon settlement of such sale).

The Company shall not be obligated to deliver any new certificate representing shares of Common Stock to Participant or Participant’s legal representative or enter such share of Common Stock in book entry form unless and until Participant or Participant’s legal representative shall have paid or otherwise satisfied in full the amount of all federal, state and local taxes applicable to the taxable income of Participant resulting from the grant of the RSUs or the issuance of shares of Common Stock.

2.7 Conditions to Delivery of Common Stock .  Subject to Section 12.4 of the Plan, the shares of Common Stock deliverable hereunder, or any portion thereof, may be either previously authorized but unissued shares of Common Stock or issued shares of Common Stock which have then been reacquired by the Company.  Such shares of Common Stock shall be fully paid and nonassessable.  The Company shall not be required to issue or deliver any shares of Common Stock deliverable hereunder or portion thereof prior to fulfillment of all of the following conditions:

(a) The admission of such shares of Common Stock to listing on all stock exchanges on which such Common Stock is then listed;

(b) The completion of any registration or other qualification of such shares of Common Stock under any state or federal law or under rulings or regulations of the Securities and Exchange Commission or of any other governmental regulatory body, which the Administrator shall, in its absolute discretion, deem necessary or advisable;

A-3

 


 

(c) The obtaining of any approval or other clearance from any state or federal governmental agency which the Administrator shall, in its absolute discretion, determine to be necessary or advisable;

(d) The receipt by the Company of all payments in connection with such shares of Common Stock, including payment of any applicable withholding tax, which may be in one or more of the forms of consideration permitted under Section 2.6(b) hereof; and

(e) The lapse of such reasonable period of time following the vesting of any Restricted Stock Units as the Administrator may from time to time establish for reasons of administrative convenience.

2.8 Rights as Stockholder .  The holder of the RSUs shall not be, nor have any of the rights or privileges of, a stockholder of the Company, including, without limitation, voting rights and rights to dividends, in respect of the RSUs and any shares of Common Stock underlying the RSUs and deliverable hereunder unless and until such shares of Common Stock shall have been issued by the Company and held of record by such holder (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).  No adjustment will be made for a dividend or other right for which the record date is prior to the date the shares of Common Stock are issued, except as provided in Section 14.2 of the Plan.  

ARTICLE 3.
OTHER PROVISIONS

3.1 Administration . The Administrator shall have the power to interpret the Plan, this Agreement and the Grant Notice and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules.  All actions taken and all interpretations and determinations made by the Administrator in good faith shall be final and binding upon Participant, the Company and all other interested persons.  No member of the Committee or the Board shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the RSUs.

3.2 Grant is Not Transferable .  During the lifetime of Participant, the RSUs may not be sold, pledged, assigned or transferred in any manner other than by will or the laws of descent and distribution, unless and until the shares of Common Stock underlying the RSUs have been issued, and all restrictions applicable to such shares of Common Stock have lapsed.  Neither the RSUs nor any interest or right therein shall be liable for the debts, contracts or engagements of Participant or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect, except to the extent that such disposition is permitted by the preceding sentence.

3.3 Binding Agreement .  Subject to the limitation on the transferability of the RSUs contained herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.

3.4 Adjustments Upon Specified Events .  The Administrator may accelerate payment and vesting of the Restricted Stock Units in such circumstances as it, in its sole discretion, may determine.  In addition, upon the occurrence of certain events relating to the Common Stock contemplated by

A-4

 


 

Article 14 of the Plan (including, without limitation, an extraordinary cash dividend on such Common Stock ), the Administrator shall make such adjustments the Administrator deems appropriate in the number of Restricted Stock Units then outstanding and the number and kind of securities that may be issued in respect of the Restricted Stock Units. Participant acknowledges that the RSUs are subject to amendment, modification and termination in certain events as provided in this Agreement and Article 1 4 of the Plan.   

3.5 Notices .  Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of the Secretary of the Company at the Company’s principal office, and any notice to be given to Participant shall be addressed to Participant at Participant’s last address reflected on the Company’s records.  By a notice given pursuant to this Section 3.5, either party may hereafter designate a different address for notices to be given to that party.  Any notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service.

3.6 Titles .  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.

3.7 Governing Law .  The laws of the Commonwealth of Massachusetts shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws.

3.8 Conformity to Securities Laws .  Participant acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and Exchange Commission thereunder, and state securities laws and regulations.  Notwithstanding anything herein to the contrary, the Plan shall be administered, and the RSUs are granted, only in such a manner as to conform to such laws, rules and regulations.  To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.

3.9 Amendments, Suspension and Termination .  To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Committee or the Board; provided that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the RSUs in any material way without the prior written consent of Participant.    

3.10 Successors and Assigns .  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth in Section 3.2 hereof, this Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.

3.11 Limitations Applicable to Section 16 Persons .  Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the RSUs and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule.  To the extent permitted by applicable law, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.  

A-5

 


 

3.12 Entire Agreement .  The Plan, the Grant Notice and this Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.

3.13 Section 409A .  The RSUs are not intended to constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, “ Section 409A ”).  However, notwithstanding any other provision of the Plan, the Grant Notice or this Agreement, if at any time the Administrator determines that the RSUs (or any portion thereof) may be subject to Section 409A, the Administrator shall have the right in its sole discretion (without any obligation to do so or to indemnify Participant or any other person for failure to do so) to adopt such amendments to the Plan, the Grant Notice or this Agreement, or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate either for the RSUs to be exempt from the application of Section 409A or to comply with the requirements of Section 409A.  No provision of this Agreement shall be interpreted or construed to transfer any liability for failure to comply with the requirements of Section 409A from Participant or any other individual to the Company or any of its affiliates, employees or agents.

3.14 Limitation on Participant’s Rights .  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and shall not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets.  Participant shall have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Common Stock as a general unsecured creditor with respect to RSUs, as and when payable hereunder.

3.15 Account Administration .  The Company may from time to time appoint a broker to administer the awards under the Plan.  To the extent the Company appoints such a broker, Participant agrees that he or she shall, upon request by the Company, open an employee brokerage services account at such broker.  

 

 

A-6

 


 

exhibit B
TO
RESTRICTED STOCK UNIT AWARD GRANT NOTICE

EMPLOYEE PATENT AND PROPRIETARY
INFORMATION UTILIZATION, NON-COMPETITION
AND NON-SOLICITATION AGREEMENT

This Employee Patent And Proprietary Information Utilization, Non-Competition and Non-Solicitation Agreement is made by and between me and Novanta Inc. (f/k/a GSI Group Inc.), a company organized under the laws of the Province of New Brunswick, Canada (together with any of its subsidiaries and Affiliates as may employ me from time to time and their respective successors and assigns, the “ Company ”) on .

1.

Consideration .  This Agreement is in consideration of the equity incentive award granted to me pursuant to that certain Restricted Stock Unit Award Grant Notice by and between the Company and me, dated as of (together with any related documents referenced therein, the “ RSU Agreement ”), and other valuable consideration, to which I hereby acknowledge I would not otherwise be entitled, including my continued employment with the Company.

2.

Proprietary Information .

(a) I understand and agree that my employment with the Company may involve access to information, whether or not in tangible form, which is the exclusive property of the Company and which is not known generally by the public, and to information which is identified as proprietary and/or confidential by the Company or which I have reason to believe is being maintained in confidence, whether embodied in memoranda, manuals, drafts, letters, drawings or other documents, computer disks, tapes or other information storage devices or any other media (“ Proprietary Information ”).  Proprietary Information may be information identified at the time of disclosure as confidential or proprietary or information which by its context would reasonably be deemed to be confidential or proprietary.  Proprietary Information includes, among other things, Inventions (as defined below), Third Party Information (as defined below), Records (as defined below), all plans regarding, and results, intermediate and final, of, the Company’s research activities in which I may participate or of which I may obtain knowledge during my employment, business, manufacturing and research methods, product designs and specifications, manufacturing procedures and tolerances, research tools, test procedures, prices and pricing formulae, cost and other financial information, customers’ special materials and product specifications and requirements, information concerning suppliers, sales records, sales reports, employee and personnel information and other human resources data, customer lists, customer contact reports, customer records, unreleased products and services, market analyses, technical notebooks, manuals and documentation, development plans, marketing and business plans, agreements with third parties, budgets, information regarding the skills and compensation of Company employees and contractors, and other non-public information regarding the Company available to me during the term of my employment.  I agree to treat Proprietary Information as confidential both during my employment and thereafter and shall recognize and protect the property rights of the Company in its Proprietary Information.

(b) I agree that all materials or media containing Proprietary Information, whether created by me or others, which comes into my custody, possession or control, are the exclusive property of the Company to be used by me only in the performance of my duties for the Company.  I will take all necessary steps to maintain the confidentiality of such information.  I will not copy or

B-1


 

remove such materials or media or copies thereof from the Company premises except in the pursuit of the business of the Company.  

(c) I also agree to maintain in confidence information disclosed to the Company by third parties, whether or not in tangible form, which is identified as confidential or proprietary under a non-disclosure or confidentiality agreement or which I have reason to believe is being maintained in confidence, or which is information of the type that would be expected to be held in confidence, whether embodied in memoranda, manuals, drafts, letters, drawings or other documents, computer disks, tapes or other information storage devices or any other media (“ Third Party Information ”).  I agree not to use Third Party Information except in the furtherance of my duties as an employee of the Company and consistent with the Company’s agreement with the applicable third party.

(d) I also represent and agree that I will not improperly use or disclose, in connection with my employment by the Company, information obtained from others, which I know to be confidential or proprietary, including information from prior employment or consulting arrangements.  I further represent that my employment with the Company will not constitute a violation of any contractual agreement with a former employer or third party, including any agreement regarding that party’s confidential or proprietary information.  I will not disclose to the Company, use in the performance of my work for the Company, or induce the Company to use, any Inventions, confidential or proprietary information, or other material belonging to any previous employer or to any other party in violation of any obligation of confidentiality to such party or in violation of such party’s proprietary rights.

(e) I shall promptly notify my supervisor or any officer of the Company if I learn of any possible unauthorized use or disclosure of Proprietary Information and shall cooperate fully with the Company to enforce its rights in such information.

(f) I acknowledge that the Company has provided me with the following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (i) I shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of Proprietary Information that is made in confidence to a federal, state or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, (ii) I shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of Proprietary Information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (iii) if I file a lawsuit for retaliation by the Company for reporting a suspected violation of law, I may disclose the Proprietary Information to my attorney and use the Proprietary Information in the court proceeding, if I file any document containing the Proprietary Information under seal, and do not disclose the Proprietary Information, except pursuant to court order.

3.

Patents and Inventions .

(a) I assign to the Company, waive all claims to moral rights to, will hold for the Company’s exclusive benefit, and will confirm assignment of in writing without compensation, my entire right, title and interest in any inventions, discoveries, techniques, processes, devices, improvements, refinements, modifications, methods, ideas, concepts, know-how, trade secrets or Works of Authorship (as defined below) conceived, made and/or reduced to practice by me, either solely or jointly with others, and whether patentable or not (“ Inventions ”), during my employment with the Company and which fall within the scope of the Company’s actual or anticipated business or research and development, whether made within or outside of my usual

B-2


 

work hours, and whether on or off Company premises (“ Employee Inventions ”) .   Notwithstanding the foregoing, I understand that this agreement does not require assignment of any Invention to the extent such Invention qualifies for protection under Section 2870 of the California Labor Code , Section 49.44.140 of the Revised Code of Washington, 765 Illinois Compiled Statutes 1060, Section 44-130 of the Kansas Statutes, or Section 181.78 of the 2010 Minnesota Statutes, the current text of each which is attached hereto as Exhibit A (such laws, the “ Invention Laws ”).  Inventions include, without limitation, software (in any form including source code and object code), algorithms, application programming interfaces (APIs), apparatus, circuit designs and assemblies, technical and business data , databases and data collections, designs, diagrams, documentation, Records, drawings, flow charts, formulae, gate arrays , materials, development plans, designs and brand elements , models, network configurations and archite ctures, photomasks, procedures , protocols, schematics, semiconductor devices, specifications, subroutines, techniques, test vectors, tools, user interfaces, developments and derivative works with respect to any of the foregoing, and any other forms of technology.  

(b) I will make prompt and full disclosure of Employee Inventions to the Company and maintain records of creative or inventive activities related thereto (“ Records ”) and deliver the Records to the Company at termination of employment or as requested by the Company.  In addition, I will promptly disclose to the Company all Inventions that I conceive, make, or reduce to specific form, either alone or jointly with others, during the period of my employment by the Company that I believe qualify under the Invention Laws, or any similar laws (each such Invention, a “ Restricted Invention ”).  At the time of disclosure of a Restricted Invention I will provide to the Company in writing evidence to substantiate the belief that such Invention qualifies as a Restricted Invention. I understand that the Company will keep in confidence any non-public information disclosed in writing to the Company by me pursuant to this Agreement relating to Restricted Inventions.  

(c) The term “ Prior Inventions ” shall mean any Inventions which I have, alone or jointly with others, conceived, developed or reduced to specific form or caused to be conceived, developed or reduced to specific form prior to the commencement of my employment with the Company that relate to the current or planned conduct of the Company.  Without limiting my obligations under Paragraph 2(d), if I use a Prior Invention in the course of my employment or incorporate a Prior Invention in any product, service or other offering of the Company, to the extent permitted by applicable law, I hereby grant Company a non-exclusive, royalty-free, perpetual and irrevocable, worldwide right to make, use, sell, import, reproduce, distribute, modify, display, perform and sublicense such Prior Invention for the purpose of developing, manufacturing, marketing, selling, supporting, and distributing Company products, services, and other Company offerings worldwide either directly or through multiple tiers of distribution.  

(d) During and after my employment with the Company, I will assist the Company, at the Company’s expense and without cost to me, in applying for, obtaining, perfecting, maintaining, enforcing, licensing, or transferring the Company’s rights in any and all countries with respect to Employee Inventions or other Inventions assigned by me to the Company, or which I am bound to assign to the Company (or any proprietary rights related thereto), and for that purpose, I will sign all documents which the Company may deem necessary or desirable.  I understand the Company may provide, by mutual agreement, legal representation to me at the Company’s expense and without cost to me, concerning issues associated with litigation involving third parties regarding any Inventions, which become the subject of this Agreement.  The mutual agreement by each of the Company and me regarding such legal representation will not be unreasonably withheld.  I further agree that if the Company is unable, after reasonable effort, to secure my signature on any documents which the Company may deem necessary or desirable in

B-3


 

applying for, obtaining, perfecting, maintaining, enforcing, licensing or transferring the Company’s rights in any and all countries with respect to Employee Inventions or other Inventions assigned by me to the Company, or which I am bound to assign to the Company (or any proprietary rights related thereto) , any executive officer of the Company shall be entitled to execute any such documents as my agent and attorney-in-fact, and I hereby irrevocably designate and appoint each executive officer of the Company as my agent and attorney-in-fact to execute any such documents on my behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Employee Invention or other Invention assigned by me to the Company, or which I am bound to assign to the Company (or any proprietary rights related thereto) , under the conditions described in this sentence.   I hereby waive and irrevocably assign to the Company any and all claims which I now or hereafter have for infringement of any and all proprietary rights assigned to the Company under this Agreement.  

4.

Works of Authorship .  I acknowledge and agree that all writings or works of authorship, including, without limitation, software program codes and/or documentation (“ Works of Authorship ”), produced or authored by me in the course of performing services for the Company, together with any copyrights on those Works of Authorship, are “works made for hire” as that term is defined in the United States Copyright Act (17 U.S.C., Section 101) and the exclusive property of the Company.  To the extent that any of the above-referenced Works of Authorship may not, by operation of law, be works made for hire, this Agreement shall constitute an irrevocable assignment by me to the Company of ownership of, and all rights of copyright in, such items, and the Company shall have the right to obtain in its own name rights of copyright, copyright registrations and similar protections which may be available in the Works of Authorship.  I agree to give the Company at its expense all assistance reasonably required to perfect such rights, including the entitlement to execute necessary documents as my agent and attorney-in-fact, as described in Paragraph 3(d) above.  

5.

Non-Competition; Non-Solicitation; Non-Disparagement .

(a) I hereby agree that I shall not, at any time during the Restricted Period, directly or indirectly engage in, have any interest in (including, without limitation, through the investment of capital or lending of money or property), or manage, operate or otherwise render any services to, any Person (whether on his or her own or in association with others, as a principal, director, officer, employee, agent, representative, partner, member, security holder, consultant, advisor, independent contractor, owner, investor, participant or in any other capacity) that engages in (either directly or through any subsidiary or Affiliate thereof) any business or activity (i) in which the Company or any of its Affiliates is engaged, or (ii) which the Company or any of its Affiliates has taken active steps to engage in or acquire, in each case, anywhere in the world (A) in which the Company or any of its Affiliates conducts any material business or activity, or (B) which the Company or any of its Affiliates has taken active steps to engage in or acquire material business or activity.  Notwithstanding the foregoing, I shall be permitted to acquire a passive stock or equity interest in such a business; provided that such stock or other equity interest acquired is not more than two percent (2%) of the outstanding interest in such business.

(b) I hereby agree that I shall not, at any time during the Restricted Period, directly or indirectly, either for myself or on behalf of any other Person, (i) recruit or otherwise solicit or induce any customer or supplier of the Company to terminate its agreement or arrangement with the Company, or otherwise change its relationship with the Company, (ii) recruit or otherwise solicit or induce any employee of the Company to terminate his or her employment or arrangement with the Company, or otherwise change his or her relationship with the Company, or

B-4


 

(iii) hire , or cause to be hired , any person who was employed by the Company at any time during the twelve (12)- month period immediately prior to the termination of my employment or who thereafter becomes employed by the Company .

(c) During the Restricted Period and thereafter, I shall not, except as required in connection with any legal dispute between the parties hereto or as required by applicable law or legal process, willfully make (or direct anyone else to make) any Disparaging remarks, comments or statements about the Company (including, without limitation, its directors, officers, agents, representatives, partners, members, equity holders or Affiliates) to any other person or entity.  For purposes hereof, “Disparaging” written or oral remarks, comments or statements are those that impugn the character, honesty, integrity or morality or business acumen or abilities in connection with any aspect of the operation of business of the individual or entity being disparaged.

(d) In the event the terms of this Paragraph 5 shall be determined by any court of competent jurisdiction to be unenforceable by reason of its extending for too great a period of time or over too great a geographical area or by reason of its being too extensive in any other respect, it will be interpreted to extend only over the maximum period of time for which it may be enforceable, over the maximum geographical area as to which it may be enforceable, or to the maximum extent in all other respects as to which it may be enforceable, all as determined by such court in such action.  Except with respect to employees whose principal place of business as of the date of termination of employment is California, any breach or violation by me of the provisions of this Paragraph 5 shall toll the running of the Restricted Period for the duration of any such breach or violation.

(e) For purposes of this Paragraph 5, (i) “ Restricted Period ” shall mean (A) with respect to employees whose principal place of business as of the date of termination of employment is California, (x) for the purposes of Paragraph 5(b)(ii), the period of employment with the Company and the one year period immediately after termination of employment for any reason and (y) for all other purposes under this Agreement, the period of employment with the Company and (B) with respect to employees whose principal place of business as of the date of termination of employment is any jurisdiction other than California, the period of employment with the Company and the one year period immediately after termination of employment for any reason, and (ii) “ Person ” shall mean any individual, natural person, corporation (including any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), incorporated or unincorporated association, governmental authority, firm, society or other enterprise, organization or other entity of any nature.

6.

Company Documents .  I agree that, upon the earlier of (a) a request by the Company and (b) the termination of my employment with the Company, I will deliver to the Company (and will not keep in my possession, reproduce or deliver to any third party) any and all Proprietary Information, Inventions, and other documents or property, or reproductions of any of the foregoing that belong to the Company (including, without limitation, any materials or media (or copies thereof) described in Paragraph 2(b)).  I further agree that any property situated on the Company’s premises and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice.  In the event of the termination of my employment with the Company for any reason, I agree to sign and deliver the “Termination Certification” attached here to as Exhibit B .  

B-5


 

7.

Notification to Other Parties .    In the event that I leave the employ of the Company, I hereby consent to notification by the Company to my new employer or any other party for whom I work about my rights and obligations under this Agreement.  

8.

Duty of Loyalty .  While employed by the Company, I agree to devote all of my business time, attention, skill and effort to the performance of my duties for the Company, and to promoting the interests and business of the Company, and I acknowledge that I owe a duty of loyalty to the Company and agree not to engage in, or contract with others to engage in, directly or indirectly, any business or other activity which is in competition with or may reasonably result in competition with the Company or which may result in other employees or other third parties terminating their relationships with the Company.

9.

Claw-Backs .

(a) In the event I breach any of my obligations under Paragraphs 2, 5(a), 5(b) or 5(c), as determined in good faith by the Company, I shall, in addition to any other remedy which may be available (i) at law or in equity, (ii) pursuant to Paragraph 13, or (iii) pursuant to the RSU Agreement, be required to pay to the Company an amount equal to all Financial Gain that I have received during the 12-month period immediately preceding (or at any time after) the date that I first breach such obligation(s).  In addition, all restricted stock units granted pursuant to the RSU Agreement (the “ RSUs ”) that have not become vested prior to the date of such breach shall thereupon be forfeited.  

(b) For purposes of this Paragraph 9, “ Financial Gain ” with respect to any specified period of time shall mean the product of (i) the number of shares of common stock of the Company subject to the RSUs that first become vested during such period and (ii) the fair market value per share of common stock of the Company as of the date the RSUs first become vested, as determined by the Company in its good faith discretion.  

10.

Affiliates of the Company .  An Affiliate of the Company shall have the same rights as the Company under this Agreement and my obligations owed to the Company under this Agreement (including, without limitation, under Paragraph 5 hereof) shall be owed to its Affiliates in the same manner as they are owed to the Company.  “ Affiliates ” of the Company shall mean (a) any Person directly or indirectly controlling, controlled by, or under common control with, the Company where “control” shall have the meaning given such term under Rule 405 of the Securities Act of 1933, as amended from time to time and (b) any other parent, affiliated or related entity and/or direct or indirect subsidiary of the Company.  This Agreement shall be binding on and inure to the benefit of the parties hereto, their legal representatives, successors and assigns; provided , that my obligations under this Agreement are personal and shall not be assigned.

11.

At-Will Employment .  I acknowledge and agree that this Agreement is not a contract of employment for any stated term and does not affect the at-will nature of my employment with the Company.  Accordingly, my employment can be terminated, without cause or notice, at my option or the Company’s option.  The at-will nature of my employment also means that I can be transferred or demoted, and my job title, compensation, benefits and other terms and conditions of employment can be reduced, without cause.  However, my execution of this Agreement and adherence to its provisions are a condition of my employment and continued employment.  This Agreement supersedes and is hereby substituted for any and all existing agreements, either verbal or written, which I have entered into with the Company relating generally to the same subject matter.

B-6


 

12.

Governing Law, Forum and Jurisdiction .   This Agreement shall be governed, construed, interpreted and enforced in accordance with the substantive laws of the Commonwealth of Massachusetts, without giving effect to any principles of conflicts of law , whether of the Commonwealth of Massachusetts or any other jurisdiction, and where applicable, the laws of the United States, that would result in the application of the laws of any other jurisdiction.  With respect to disputes and claims hereunder, each of the parties irrevocably submits to the exclusive jurisdiction of any court of competent jurisdiction sitting in Middlesex County, Massachusetts, for the purposes of any suit, action or other proceeding arising out of this Agreement, any related agreement or any transaction contemplated hereby or thereby.  Each of the parties hereto irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement, any related document or the transactions contemplated hereby and thereby in any court of competent jurisdiction sitting in Middlesex County, Massachusetts, and hereby and thereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.

13.

Employee Acknowledgement and Equitable Remedies .  I acknowledge and agree that the restrictions and obligations contained in this Agreement are necessary for the protection of the business of the Company, and I consider these restrictions and obligations to be reasonable for such purpose.  I agree that any breach of this Agreement by me is likely to cause the Company and its goodwill substantial and irrevocable damage, the exact amount of which will be difficult or impossible to ascertain, and that a breach of this Agreement would entail inevitable wrongful use or disclosure of Proprietary Information.  Therefore, I agree that, upon receiving notice of any actual or threatened breach of this Agreement, the Company may seek relief in the form of specific performance, temporary or permanent injunctions or restraining orders, in each case which may mandate compliance with or prohibit violation of this Agreement, and I waive any requirement for the security or posting of any bond in connection with any such remedy.  Such remedies shall not be the exclusive remedies for breach of this Agreement but shall be in addition to all other remedies available at law or in equity to the Company.

14.

Amendment; Waiver .  No modification or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by the party to be charged.  The waiver by any party hereto expressed or implied, or any breach hereunder shall not be deemed a continuing waiver or consent to a subsequent breach.  The failure of any party hereto at any time to require performance of any provision hereof shall in no way effect the right to require performance at any time thereafter.  The waiver of any party to a breach of any provision hereof shall not be a waiver of the enforceability of such provision itself.

15.

Interpretation .  In the event that any provision of this Agreement conflicts with the law under which this Agreement is to be construed or, if any such provision is held invalid by a court with jurisdiction over the parties to this Agreement, unless otherwise provided in Paragraph 5(d), such provision shall be deemed to be restated to reflect as nearly as possible the original intentions of the parties in accordance with applicable law, and the remainder of this Agreement shall remain in full force and effect.  Notwithstanding anything to the contrary herein, nothing in this Agreement shall be interpreted to prohibit me from exercising my rights under the National Labor Relations Act, including, without limitation, discussing the terms and conditions of my employment.

16.

Severability .  The invalidity or unenforceability of any provision of this Agreement shall not affect or impair the validity or enforceability of any other provision of this Agreement.

B-7


 

17.

Entire Agreement . This Agreement sets forth the entire agreement and understanding between the Company and me relating to the subject matter herein and merges all prior discussions between us. Any subsequent change or changes in my duties, obligations, rights or compensation will not affect the validity or scope of this Agreement. The provisions of this Agreement shall survive the termination of my employment with the Company for any reason and the assignment of this Agreement by the Company to any successor in interest or other assignee. This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.   I acknowledge that, in executing this Agreement, I have had the opportunity to seek the advice of indepe ndent legal counsel and I have read and understood all of the terms and provisions of this Agreement.  This Agreement shall not be construed against any party by reason of the drafting or preparation hereof.

[signature page follows]

 

B-8


 

The parties have executed this Agreement on the first date set forth above:

 

NOVANTA, INC.

 

 

Name:

Title:

 

 

 

 

 

 

 

 

 

Signature Page to Employee Patent and Proprietary Information Utilization,

Non-Competition and Non-Solicitation Agreement

B-9


 

Exhibit A

 

Section 2870 of the California Labor Code

As of the date of this Agreement, Section 2870 of the California Labor Code is as follows:  

(a)

Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either:

(1) Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or

(2) Result from any work performed by the employee for the employer.

(b)

To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.


B-10


 

Section 49.44.140 of the Revised Code of Washington

As of the date of this Agreement, 49.44.140 of the Revised Code of Washington is as follows:  

(1)

A provision in an employment agreement which provides that an employee shall assign or offer to assign any of the employee's rights in an invention to the employer does not apply to an invention for which no equipment, supplies, facilities, or trade secret information of the employer was used and which was developed entirely on the employee's own time, unless (a) the invention relates (i) directly to the business of the employer, or (ii) to the employer's actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by the employee for the employer. Any provision which purports to apply to such an invention is to that extent against the public policy of this state and is to that extent void and unenforceable.

(2)

An employer shall not require a provision made void and unenforceable by subsection (1) of this section as a condition of employment or continuing employment.

(3)

If an employment agreement entered into after September 1, 1979, contains a provision requiring the employee to assign any of the employee's rights in any invention to the employer, the employer must also, at the time the agreement is made, provide a written notification to the employee that the agreement does not apply to an invention for which no equipment, supplies, facility, or trade secret information of the employer was used and which was developed entirely on the employee's own time, unless (a) the invention relates (i) directly to the business of the employer, or (ii) to the employer's actual or demonstrably anticipated research or development, or (b) the invention results from any work preformed [performed] by the employee for the employer.


B-11


 

765 Illinois Compiled Statutes 1060

As of the date of this Agreement, 765 Illinois Compiled Statutes 1060 is as follows:  

(1)

A provision in an employment agreement which provides that an employee shall assign or offer to assign any of the employee's rights in an invention to the employer does not apply to an invention for which no equipment, supplies, facilities, or trade secret information of the employer was used and which was developed entirely on the employee's own time, unless (a) the invention relates (i) to the business of the employer, or (ii) to the employer's actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by the employee for the employer. Any provision which purports to apply to such an invention is to that extent against the public policy of this State and is to that extent void and unenforceable. The employee shall bear the burden of proof in establishing that his invention qualifies under this subsection.

(2)

An employer shall not require a provision made void and unenforceable by subsection (1) of this Section as a condition of employment or continuing employment. This Act shall not preempt existing common law applicable to any shop rights of employers with respect to employees who have not signed an employment agreement.

(3)

If an employment agreement entered into after January 1, 1984, contains a provision requiring the employee to assign any of the employee's rights in any invention to the employer, the employer must also, at the time the agreement is made, provide a written notification to the employee that the agreement does not apply to an invention for which no equipment, supplies, facility, or trade secret information of the employer was used and which was developed entirely on the employee's own time, unless (a) the invention relates (i) to the business of the employer, or (ii) to the employer's actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by the employee for the employer.


B-12


 

Section 44-130 of the Kansas Statutes

As of the date of this Agreement, Section 44-130 of the Kansas Statutes is as follows:  

(a)

Any provision in an employment agreement which provides that an employee shall assign or offer to assign any of the employee's rights in an invention to the employer shall not apply to an invention for which no equipment, supplies, facilities or trade secret information of the employer was used and which was developed entirely on the employee's own time, unless:

(1)   The invention relates to the business of the employer or to the employer's actual or demonstrably anticipated research or development; or

(2)   the invention results from any work performed by the employee for the employer.

(b)        Any provision in an employment agreement which purports to apply to an invention which it is prohibited from applying to under subsection (a), is to that extent against the public policy of this state and is to that extent void and unenforceable. No employer shall require a provision made void and unenforceable by this section as a condition of employment or continuing employment.

(c)         If an employment agreement contains a provision requiring the employee to assign any of the employee's rights in any invention to the employer, the employer shall provide, at the time the agreement is made, a written notification to the employee that the agreement does not apply to an invention for which no equipment, supplies, facility or trade secret information of the employer was used and which was developed entirely on the employee's own time, unless:

(1)   The invention relates directly to the business of the employer or to the employer's actual or demonstrably anticipated research or development; or

(2)   the invention results from any work performed by the employee for the employer.

(d)         Even though the employee meets the burden of proving the conditions specified in this section, the employee shall disclose, at the time of employment or thereafter, all inventions being developed by the employee, for the purpose of determining employer and employee rights in an invention.


B-13


 

Section 181.78 of the 2010 Minnesota Statutes

As of the date of this Agreement, Section 181.78 of the 2010 Minnesota Statutes is as follows:  

Subdivision 1. Inventions not related to employment.

Any provision in an employment agreement which provides that an employee shall assign or offer to assign any of the employee's rights in an invention to the employer shall not apply to an invention for which no equipment, supplies, facility or trade secret information of the employer was used and which was developed entirely on the employee's own time, and (1) which does not relate (a) directly to the business of the employer or (b) to the employer's actual or demonstrably anticipated research or development, or (2) which does not result from any work performed by the employee for the employer. Any provision which purports to apply to such an invention is to that extent against the public policy of this state and is to that extent void and unenforceable.

Subd. 2. Effect of subdivision 1.

No employer shall require a provision made void and unenforceable by subdivision 1 as a condition of employment or continuing employment.

Subd. 3. Notice to employee.

If an employment agreement entered into after August 1, 1977 contains a provision requiring the employee to assign or offer to assign any of the employee's rights in any invention to an employer, the employer must also, at the time the agreement is made, provide a written notification to the employee that the agreement does not apply to an invention for which no equipment, supplies, facility or trade secret information of the employer was used and which was developed entirely on the employee's own time, and (1) which does not relate (a) directly to the business of the employer or (b) to the employer's actual or demonstrably anticipated research or development, or (2) which does not result from any work performed by the employee for the employer.


B-14


 

Exhibit B

Termination Certification

This is to certify that I do not have in my possession, nor have I failed to return, any records, data, software, equipment, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, technical notebooks, charts, materials, equipment, other documents or property, or copies or reproductions of any of the foregoing items belonging to Novanta Inc. (f/k/a GSI Group Inc.), its subsidiaries, affiliates, successors, or assigns (collectively the “ Company ”) or the Company’s customers, suppliers or business partners.

I further certify that I have complied with all the terms of the Company’s Employee Patent and Proprietary Information Utilization, Non-Competition and Non-Solicitation Agreement signed by me (the “ Agreement ”), including the reporting of any Inventions (as defined therein) covered by the Agreement.

I further agree that, in compliance with the Agreement, I will preserve as confidential all Proprietary Information (as defined therein) after the termination of my employment with the Company.

I further agree that, in compliance with the Agreement, for the Restricted Period (as defined in the Agreement), I have and will comply with the provisions of Paragraph 5 thereof.

 

Date:

 

( Employee’s Signature )

 

( Type/Print Employee’s Name )

B-15

 

E xhibit 10.2

 

NOVANTA inc.

2010 incentive award PLAN

 

PERFORMANCE STOCK UNIT AWARD GRANT NOTICE

 

Novanta Inc., a company organized under the laws of the Province of New Brunswick, Canada (the “ Company ”), pursuant to its 2010 Incentive Award Plan, as amended from time to time (the “ Plan ”), hereby grants to the holder listed below (“ Participant ”) an award of performance stock units (the “ Performance Stock Units ”).  Each Performance Stock Unit represents the right to receive a number of shares of Common Stock (as defined in the Plan) equal to the Settlement Amount (as described below) upon the achievement of certain performance goals.  This award of Performance Stock Units is subject to all of the terms and conditions set forth herein and in the Performance Stock Unit Award Agreement attached hereto as Exhibit A (the “ Performance Stock Unit Award Agreement ”) and the Plan, each of which is incorporated herein by reference.  

Participant:

 

Grant Date:

 

Number of Performance Stock Units:

 

Performance Years:

 

Performance Goals:

Annual Adjusted EPS Performance Goals

 

Fiscal year ending December 31:

Threshold Adjusted EPS

Target Adjusted EPS

Maximum Adjusted EPS

 

Cumulative Adjusted EPS Performance Goals

Threshold Cumulative Adjusted EPS:

Target Cumulative Adjusted EPS:

Maximum Cumulative Adjusted EPS:

 


 

Settlement Amount:

“Settlement Amount” means the aggregate number of shares of Common Stock received in settlement of the EPS Performance Stock Units and TSR Performance Stock Units (each as defined below) as described below:

(1) A tranche of         % of the Performance Stock Units (the “ EPS Performance Stock Units ”) shall settle in a number of shares of Common Stock equal to:

(a) If Cumulative Adjusted EPS is less than Threshold Cumulative Adjusted EPS:       % of the number of vested EPS Performance Stock Units;

(b) If Cumulative Adjusted EPS equals Threshold Cumulative Adjusted EPS:       % of the number of vested EPS Performance Stock Units;

(c) If Cumulative Adjusted EPS equals Target Cumulative Adjusted EPS:          % of the number of vested EPS Performance Stock Units; and

(d) If Cumulative Adjusted EPS equals or exceeds Maximum Cumulative Adjusted EPS:        % of the number of vested EPS Performance Stock Units; in each case of subsections (b) through (d), with linear interpolation for Cumulative Adjusted EPS between applicable Performance Goals.  

(2) The remaining tranche of         % of the Performance Stock Units (the “ TSR Performance Stock Units ”) shall settle in a number of shares of Common Stock equal to:

(a) If Total Shareholder Return is less than the Index TSR: A percentage of the number of vested TSR Performance Stock Units equal to (i)             % minus (ii) the product of (A)           and (B) the TSR Spread;

(b) If Total Shareholder Return equals the Index TSR:            % of the number of vested TSR Performance Stock Units (the “ TSR Target Amount ”);

(c) If Total Shareholder Return exceeds the Index TSR: A percentage of the number of vested TSR Performance Stock Units equal to (i)             % plus (ii) the product of (A)           and (B) the TSR Spread;

provided that, notwithstanding the foregoing, if Total Shareholder Return is a negative amount, the maximum settlement amount shall in no event exceed the TSR Target Amount.

By his or her signature below, Participant agrees to be bound by the terms and conditions of the Plan, the Performance Stock Unit Award Agreement and this Grant Notice.  Participant has reviewed the Performance Stock Unit Award Agreement, the Plan and this Grant Notice in their entirety, and fully understands all provisions of this Grant Notice, the Performance Stock Unit Award Agreement and the Plan.

NOVANTA INC.:

PARTICIPANT:

By:

 

By:

 

Print Name:

 

 

Name:  

 

 

Title:

 

  

 

Address:

 

Address:

 

 

 

 

 

 

 

 

 

 

 


 

EXHIBIT A

TO PERFORMANCE STOCK UNIT AWARD GRANT NOTICE

PERFORMANCE STOCK UNIT AWARD AGREEMENT

Pursuant to the Performance Stock Unit Award Grant Notice (the “ Grant Notice ”) to which this Performance Stock Unit Award Agreement (this “ Agreement ”) is attached, Novanta Inc., a company organized under the laws of the Province of New Brunswick, Canada (the “ Company ”), has granted to Participant performance stock units (the “ Performance Stock Units ”) under the Novanta Inc. 2010 Incentive Award Plan, as amended from time to time (the “ Plan ”).  

ARTICLE 1.
GENERAL

1.1 Defined Terms .  Capitalized terms not specifically defined herein shall have the meanings specified in the Grant Notice and the Plan.  

(a) Adjusted Earnings ” means, with respect to any Performance Year, the Company’s non-GAAP net income for such Performance Year calculated in accordance with the same methodology used to calculate such non-GAAP metric as reported in the Company’s earnings press release in the Company’s Current Report on Form 8-K furnished to the Securities and Exchange Commission for such Performance Year.

(b) Adjusted EPS ” means, with respect to any Performance Year, the Adjusted Earnings for such Performance Year divided by the diluted weighted average number of shares of Common Stock outstanding for such Performance Year calculated in accordance with the same methodology used to calculate Adjusted EPS as reported in the Company’s earnings press release in the Company’s Current Report on Form 8-K furnished to the Securities and Exchange Commission for such Performance Year.

(c) Cause ” shall have the meaning of “Cause” (or similar term) set forth in Participant’s written employment agreement or, if no such written employment agreement (or no definition of “Cause” or similar term therein), shall mean (i) Participant’s willful failure to substantially perform the duties set forth in any written employment agreement (other than any such failure resulting from Participant’s Disability); (ii) Participant’s willful failure to carry out, or comply with, in any material respect any lawful and reasonable directive of the Board (or his or her supervisor); (iii) Participant’s commission at any time of any act or omission that results in, or may reasonably be expected to result in, a conviction, plea of no contest, plea of nolo contendere , or imposition of unadjudicated probation for any felony or crime involving moral turpitude; or (iv) Participant’s unlawful use (including being under the influence) or possession of illegal drugs on the Company’s premises or while performing Participant’s duties and responsibilities for the Company.

(d) CIC Qualifying Termination ” shall mean Termination of Service of Participant by the Company without Cause or by Participant for Good Reason during the twelve (12)-month period immediately following a Qualifying Change in Control.  For the avoidance of doubt, in the event the terms and conditions of any employment or similar agreement between Participant and the Company conflict with this Agreement with respect to the treatment of the Performance Stock Units upon a CIC Qualifying Termination, the terms and conditions of the employment or similar agreement will control.

 


 

(e) Cumulative Adjusted EPS ” means the sum of Adjusted EPS for all Performance Years; provided that, if a Qualifying Change in Control occurs, Cumulative Adjusted EPS shall equal the Target Cumulative Adjusted EPS (as set forth in the Grant Notice).  

(f) Determination Date ” means                              .  

(g) Disability ” shall mean Participant’s inability to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that can be expected to last for (i) a continuous period of not less than 90 days or (ii) at least 180 total calendar days in any 12-month period, in each case as determined by a physician selected by the Company or its insurers and reasonably acceptable to Participant. The Company will inform Participant of the selection of the physician so that Participant may consent to such selection (and Participant’s  consent shall not be unreasonably withheld). Participant shall be deemed to have consented to the selection of the physician if Participant does not provide the Company with written notice objecting to such selection within five business days of Participant being informed of the physician's selection. If Participant objects to such selection (and the Company determines in good faith that such withholding is not unreasonable), then the Company shall select another physician pursuant to the process described in this Section 1.1(f).

(h) Good Reason ” shall have the meaning of “Good Reason” (or similar term) set forth in Participant’s written employment agreement or, if no such written employment agreement (or no definition of “Good Reason” or similar term therein), Participant shall have “Good Reason” to terminate his or her employment within one (1) year after the occurrence of one or more of the following conditions without Participant’s consent: (i) a material diminution in the nature or scope of Participant’s responsibilities, duties or authority; or (ii) a material change in the geographic location at which Participant must perform Participant’s material services to the Company (which shall in no event include a relocation of Participant’s principal place of business less than 50 miles from its location as of the Grant Date); provided , however, that, notwithstanding the foregoing, Participant may not resign his employment for Good Reason unless: (A) Participant provides the Company with at least 30 days prior written notice of his or her intent to resign for Good Reason (which notice is provided not later than the 90th day following Participant’s knowledge of the occurrence of the event constituting Good Reason); and (B) the Company does not remedy the alleged violation(s) within such 30-day period.

(i) Index TSR ” means the percentage appreciation in the twenty (20) consecutive trading day trailing average (rounded to the nearest cent) of the closing price of                 (“                ”) for the twenty (20) trading day period ending on, and including,                         (such trailing average closing price, the “ Initial                 Price ”) to the last day of the Performance Period (or, if a Qualifying Change in Control occurs, the date of the Qualifying Change in Control), determined by dividing (i) the difference obtained by subtracting (A) the Initial                     Price, from (B) the twenty (20) consecutive trading day trailing average (rounded to the nearest cent) of the closing price of   for the twenty (20) trading day period ending on, and including, the last day of the Performance Period or, if a Qualifying Change in Control occurs, the date of such Qualifying Change in Control (or, if the last day of the Performance Period or the date of a Qualifying Change in Control, as applicable, is not a trading day, the most recent trading day immediately preceding such date) by (ii) the Initial Price (and rounding such amount to the nearest tenth of a percent).

(j) Performance Period ” means the period commencing on                       and ending on                           .

(k) Performance Year ” means each of the 12-month periods starting on January 1 and ending on December 31 within the Performance Period.

 


 

(l) Qualifying Change in Control ” means a Change in Control consummated prior to the last day of the Performance Period.

(m) Total Shareholder Return ” means the percentage appreciation in the TSR Starting Common Stock Price to the TSR Final Common Stock Price, determined by dividing (i) the difference obtained by subtracting (A) the TSR Starting Common Stock Price, from (B) the TSR Final Common Stock Price on the last day of the Performance Period or, if a Qualifying Change in Control occurs, the date of such Qualifying Change in Control, plus all dividends declared on a share of Common Stock from the Grant Date to the last day of the Performance Period or the date of a Qualifying Change in Control, as applicable, by (ii) the TSR Starting Common Stock Price (and rounding such amount to the nearest tenth of a percent).  Additionally, as set forth in, and pursuant to, Section 3.4, appropriate adjustments to the Total Shareholder Return shall be made to take into account all stock dividends, stock splits, reverse stock splits and the other events set forth in Section 3.4 that occur between the Grant Date and the last day of the Performance Period or the date of a Qualifying Change in Control, as applicable.

(n) TSR Final Common Stock Price ” means the twenty (20) consecutive trading day trailing average (rounded to the nearest cent) of the Fair Market Value for the twenty (20) trading day period ending on, and including, the last day of the Performance Period (or, if the last day of the Performance Period is not a trading day, the most recent trading day immediately preceding such date); provided that, if a Qualifying Change in Control occurs, the TSR Final Common Stock Price as of the date of such Qualifying Change in Control and thereafter shall be equal to (i) with respect to a Qualifying Change in Control described in Section 2.10(a) or (c) of the Plan, the fair market value, as determined by the Committee or the Board, of the total consideration paid or payable in the transaction resulting in such Change in Control for one share of Common Stock, and (ii) with respect to a Qualifying Change in Control described in Section 2.10(b) or (d) of the Plan, the twenty (20) consecutive trading day trailing average (rounded to the nearest cent) of the Fair Market Value for the twenty (20) trading day period ending on, and including, the date of such Qualifying Change in Control (or, if such date is not a trading day, the most recent trading day immediately preceding such date).

(o) TSR Spread ” means the difference between Total Shareholder Return and the Index TSR (each represented as a percentage), up to a maximum of             percent (       %), in all cases represented as a positive percentage.  For example, (i) if Total Shareholder Return were to equal thirty percent (30.0%) and Index TSR were to equal eighteen percent (18.0%), TSR Spread would equal twelve percent (12.0%) and the TSR Performance Stock Units would settle in a number of shares of Common Stock equal to                 percent (       %) (i.e.,            % plus (                x 12.0%)) of the number of vested TSR Performance Stock Units; and (ii) if Total Shareholder Return were to equal eighteen percent (18.0%) and Index TSR were to equal thirty percent (30.0%), TSR Spread would equal twelve percent (12.0%) and the TSR Performance Stock Units would settle in a number of shares of Common Stock equal to           percent (       %) (i.e.,           % minus (               x 12.0%)) of the number of vested TSR Performance Stock Units.

(p) TSR Starting Common Stock Price ” means $                   .

1.2 Incorporation of Terms of Plan .  The Performance Stock Units are subject to the terms and conditions of the Plan, which are incorporated herein by reference.  In the event of any conflict between the provisions of this Agreement and the Plan, the terms of the Plan shall control.

 


 

ARTICLE 2.
PERFORMANCE STOCK UNITS

2.1 Grant of Performance Stock Units .  In consideration of Participant’s past and/or continued employment with or service to the Company or a Subsidiary and for other good and valuable consideration, effective as of the Grant Date, the Company grants to Participant an award of Performance Stock Units as set forth in the Grant Notice, upon the terms and conditions set forth in the Plan and this Agreement , subject to adjustments as provided in Article 14 of the Plan.  

2.2 Company’s Obligation to Pay .  Each Performance Stock Unit is a unit of measurement based on the Fair Market Value of a share of Common Stock that may entitle Participant to receive a payment in shares of Common Stock following the date it becomes vested.  Unless and until the Performance Stock Units will have vested in the manner set forth in Article 2 hereof, Participant will have no right to payment of any such Performance Stock Units.  Prior to actual payment in respect of any vested Performance Stock Units, such Performance Stock Units will represent an unsecured obligation of the Company, payable (if at all) only from the general assets of the Company.  

2.3 Vesting . Subject to Sections 2.4 and 2.5 hereof, all Performance Stock Units will, subject to Participant’s continued employment or services through                    , vest and become nonforfeitable on                         and shall be subject to settlement with respect to the number of shares of Common Stock as described on the Grant Notice and at the time set forth in Section 2.6.  

2.4 CIC Qualifying Termination . Notwithstanding the Grant Notice or the provisions of Sections 2.3 and 2.5(a) hereof, but subject to the terms of the Plan (and after taking into account any forfeiture under Section 2.5(d)), in the event of a CIC Qualifying Termination, all Performance Stock Units will vest and become nonforfeitable on the date of the CIC Qualifying Termination.

2.5 Forfeiture, Termination and Cancellation .  Notwithstanding any contrary provision of this Agreement:

(a) Except as otherwise set forth in Section 2.4 or as otherwise determined by the Administrator consistent with the Plan, upon Participant’s Termination of Service for any or no reason, all then unvested Performance Stock Units subject to this Agreement will thereupon be automatically forfeited, terminated and cancelled as of the date of Termination of Service without payment of any consideration by the Company, and Participant, or Participant’s beneficiary or personal representative, as the case may be, shall have no further rights hereunder.

(b) If, on or prior to the Determination Date, Cumulative Adjusted EPS is determined by the Administrator to be less than Threshold Cumulative Adjusted EPS , then any outstanding EPS Performance Stock Units shall automatically be forfeited by Participant on the date of such determination, and Participant, or Participant’s beneficiary or personal representative, as the case may be, shall have no further rights hereunder.

(c) If, on or prior to the Determination Date, (i) Total Shareholder Return is determined by the Administrator to be less than Index TSR and (ii) the TSR Spread equals or exceeds                                 , then any outstanding TSR Performance Stock Units shall automatically be forfeited by Participant on the date of such determination, and Participant, or Participant’s beneficiary or personal representative, as the case may be, shall have no further rights hereunder.

 


 

(d) If, on the date of a Qualifying Change in Control , (i) Total Shareholder Return is determined by the Administrator to be less than Index TSR and (ii) the TSR Spread equals or exceeds , then any outstanding TSR Performance Stock Units shall automatically be forfeited by Participant on such date, and Participant, or Participant’s beneficiary or personal representative, as the case may be, shall have no further rights hereunder.

2.6 Payment Following Vesting .  

(a) As soon as administratively practicable on or following the end of the Performance Period or, if earlier, the date of a CIC Qualifying Termination (but in no event later than the Determination Date or, if earlier, the date of a CIC Qualifying Termination) (for the avoidance of doubt, this deadline is intended to comply with the “short-term deferral” exemption from Section 409A of the Code), the Company shall deliver to Participant (or any transferee permitted under Section 3.2 hereof) a number of shares of Common Stock (either by delivering one or more certificates for such shares or by entering such shares in book entry form, as determined by the Company in its sole discretion) equal to the Settlement Amount, unless such Performance Stock Units terminate prior to the given vesting date pursuant to Section 2.5 hereof.   Notwithstanding anything to the contrary contained herein, the exact date of issuance of shares of Common Stock in respect of the Performance Stock Units during the period set forth in this Section 2.6(a) shall be determined by the Company in its sole discretion (and Participant shall not have a right to designate the time of payment). Notwithstanding the foregoing, in the event shares of Common Stock cannot be issued pursuant to Section 2.7(a), (b) or (c) hereof, then the shares of Common Stock shall be issued pursuant to the preceding sentence as soon as administratively practicable after the Administrator determines that shares of Common Stock can again be issued in accordance with Sections 2.7(a), (b) and (c) hereof.

(b) Notwithstanding anything to the contrary in this Agreement, the Company shall be entitled to require payment by Participant of any sums required by applicable law to be withheld with respect to the grant and/or vesting of Performance Stock Units or the issuance of shares of Common Stock.  Such payment shall be made by deduction from other compensation payable to Participant or in the following other form(s) of consideration (as determined appropriate by the Administrator):

(i) Cash or check;

(ii) Surrender of shares of Common Stock (including, without limitation, shares of Common Stock otherwise issuable under the Performance Stock Units) held for such period of time as may be required by the Administrator in order to avoid adverse accounting consequences and having a Fair Market Value on the date of delivery equal to the amount required to be withheld based on the maximum statutory withholding rates in Participant’s applicable jurisdictions in accordance with Section 12.2 of the Plan; or

(iii) Other property acceptable to the Administrator (including, without limitation, through the delivery of a notice that Participant has placed a market sell order with a broker with respect to shares of Common Stock then issuable under the Performance Stock Units, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of its withholding obligations; provided that payment of such proceeds is then made to the Company upon settlement of such sale).

The Company shall not be obligated to deliver any new certificate representing shares of Common Stock to Participant or Participant’s legal representative or enter such share of Common Stock in book entry form unless and until Participant or Participant’s legal representative shall have paid or otherwise satisfied in full the amount of all federal, state and local taxes applicable to the taxable income of Participant

 


 

resulting from the grant of the Performance Stock Units or the issuance of shares of Common Stock. To the extent that any Federal Insurance Contributions Act tax withholding obligations arise in connection with the Performance Stock Units prior to the applicable vesting or payment date, the Administrator may accelerate the payment in respect of a portion of the award of Performance Stock Units sufficient to satisfy (but not in excess of) such tax withholding obligations and any tax withholding obligations associated with any such accelerated payment, and the Administrator shall withhold such amounts in satisfaction of such withholding obligations.

2.7 Conditions to Delivery of Common Stock .  Subject to Section 12.4 of the Plan, the shares of Common Stock deliverable hereunder, or any portion thereof, may be either previously authorized but unissued shares of Common Stock or issued shares of Common Stock which have then been reacquired by the Company. Such shares of Common Stock shall be fully paid and nonassessable.  The Company shall not be required to issue or deliver any shares of Common Stock deliverable hereunder or portion thereof prior to fulfillment of all of the following conditions:

(a) The admission of such shares of Common Stock to listing on all stock exchanges on which such Common Stock is then listed;

(b) The completion of any registration or other qualification of such shares of Common Stock under any state or federal law or under rulings or regulations of the Securities and Exchange Commission or of any other governmental regulatory body, which the Administrator shall, in its absolute discretion, deem necessary or advisable;

(c) The obtaining of any approval or other clearance from any state or federal governmental agency which the Administrator shall, in its absolute discretion, determine to be necessary or advisable;

(d) The receipt by the Company of all payments in connection with such shares of Common Stock, including payment of any applicable withholding tax, which may be in one or more of the forms of consideration permitted under Section 2.6(b) hereof; and

(e) The lapse of such reasonable period of time following the end of the Performance Period or the date of a CIC Qualifying Termination, as applicable, as the Administrator may from time to time establish for reasons of administrative convenience (provided that delivery of shares of Common Stock shall in all events comply with the “short-term deferral” exemption from Section 409A of the Code).

2.8 Rights as Stockholder .  The holder of the Performance Stock Units shall not be, nor have any of the rights or privileges of, a stockholder of the Company, including, without limitation, voting rights and rights to dividends, in respect of the Performance Stock Units and any shares of Common Stock underlying the Performance Stock Units and deliverable hereunder unless and until such shares of Common Stock shall have been issued by the Company and held of record by such holder (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).  No adjustment will be made for a dividend or other right for which the record date is prior to the date the shares of Common Stock are issued, except as provided in Section 14.2 of the Plan.

 


 

ARTICLE 3.

OTHER PROVISIONS

3.1 Administration .  The Administrator shall have the power to interpret the Plan, this Agreement and the Grant Notice and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules.  All actions taken and all interpretations and determinations made by the Administrator (including, without limitation, determinations, interpretations and assumptions with respect to the Performance Goals) in good faith shall be final and binding upon Participant, the Company and all other interested persons.  No member of the Committee or the Board shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the Performance Stock Units.

3.2 Grant is Not Transferable .  During the lifetime of Participant, the Performance Stock Units may not be sold, pledged, assigned or transferred in any manner other than by will or the laws of descent and distribution, unless and until the shares of Common Stock underlying the Performance Stock Units have been issued, and all restrictions applicable to such shares of Common Stock have lapsed.  Neither the Performance Stock Units nor any interest or right therein shall be liable for the debts, contracts or engagements of Participant or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect, except to the extent that such disposition is permitted by the preceding sentence.

3.3 Binding Agreement .  Subject to the limitation on the transferability of the Performance Stock Units contained herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.

3.4 Adjustments Upon Specified Events .  The Administrator may accelerate payment and vesting of the Performance Stock Units in such circumstances as it, in its sole discretion, may determine.  In addition, upon the occurrence of certain events relating to the Common Stock contemplated by Section 14.2 of the Plan (including, without limitation, an extraordinary cash dividend on such Common Stock), the Administrator shall make such adjustments the Administrator deems appropriate in the number of Performance Stock Units then outstanding and the number and kind of securities that may be issued in respect of the Performance Stock Units.  Participant acknowledges that the Performance Stock Units are subject to amendment, modification and termination in certain events as provided in this Agreement and Article 14 of the Plan.  

3.5 Notices .  Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of the Secretary of the Company at the Company’s principal office, and any notice to be given to Participant shall be addressed to Participant at Participant’s last address reflected on the Company’s records.  By a notice given pursuant to this Section 3.5, either party may hereafter designate a different address for notices to be given to that party.  Any notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service.

3.6 Titles .  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.

 


 

3.7 Governing Law .  The laws of the Commonwealth of Massachusetts shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws.

3.8 Conformity to Securities Laws .  Participant acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and Exchange Commission thereunder, and state securities laws and regulations.  Notwithstanding anything herein to the contrary, the Plan shall be administered, and the Performance Stock Units are granted, only in such a manner as to conform to such laws, rules and regulations.  To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.

3.9 Amendments, Suspension and Termination .  To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Committee or the Board; provided that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the Performance Stock Units in any material way without the prior written consent of Participant.    

3.10 Successors and Assigns .  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth in Section 3.2 hereof, this Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.

3.11 Limitations Applicable to Section 16 Persons .  Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Performance Stock Units and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule.  To the extent permitted by applicable law, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.

3.12 Not a Contract of Service .  Nothing in this Agreement or in the Plan shall confer upon Participant any right to continue to serve as an Employee, Director, Consultant or other service provider of the Company or any of its Subsidiaries or shall interfere with or restrict in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.

3.13 Entire Agreement .  The Plan, the Grant Notice and this Agreement (including all exhibits thereto, if any) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and its Subsidiaries and Participant with respect to the subject matter hereof.

3.14 Section 409A . The Performance Stock Units are not intended to constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, “ Section 409A ”).  

 


 

However, notwithstanding any other provision of the Plan, the Grant Notice or this Agreement, if at any time the Administrator determines that the Performance Stock Units (or any portion thereof) may be subject to Section 409A, the Administrator shall have the right in its sole discretion (without any obligation to do so or to indemnify Participant or any other person for failure to do so) to adopt such amendments to the Plan, the Grant Notice or this Agreement, or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate either for the Performance Stock Units to be exempt from the application of Section 409A or to comply with the requirements of Section 409A.

3.15 Limitation on Participant’s Rights .  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and shall not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets.  Participant shall have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Performance Stock Units, and rights no greater than the right to receive the Common Stock as a general unsecured creditor with respect to Performance Stock Units, as and when payable hereunder.

3.16 Account Administration .  The Company may from time to time appoint a broker to administer the awards under the Plan.  To the extent the Company appoints such a broker, Participant agrees that he or she shall, upon request by the Company, open an employee brokerage services account at such broker.  

 

 

Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, Matthijs Glastra, certify that:

1.

I have reviewed this quarterly report on Form 10-Q of Novanta Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 8, 2017

 

/s/ Matthijs Glastra

Matthijs Glastra

Chief Executive Officer

 

 

Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, Robert J. Buckley, certify that:

1.

I have reviewed this quarterly report on Form 10-Q of Novanta Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 8, 2017

 

/s/ Robert J. Buckley

Robert J. Buckley

Chief Financial Officer

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Novanta Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Matthijs Glastra, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) the Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Matthijs Glastra

Matthijs Glastra

Chief Executive Officer

May 8, 2017

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Novanta Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert J. Buckley, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) the Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Robert J. Buckley

Robert J. Buckley

Chief Financial Officer

May 8, 2017